

A Work Project, presented as part of the requirements for the Award of a Master's degree in
Management from the Nova School of Business and Economics.

BUSINESS OPPORTUNITIES AND RISKS FOR GERMAN
PHARMACEUTICAL SMEs IN ASIA – AN EXAMINATION OF THE
PHARMACEUTICAL MARKETS IN MALAYSIA

Annika Hanfmann (49730)

Work Project carried out under the supervision of:

Prof. Andrew Harrison

25/01/2023

Acknowledgements

First and foremost, we are grateful for the supervision by Prof. Andrew Harrison who always supported us with his guidance, valuable advice, and humorous manner during our Field Lab. Furthermore, we would like to thank the institution of Nova SBE that enabled us to grow on a professional and personal level.

Abstract

This paper analyzes business opportunities and risks for German pharmaceutical small- and medium-sized enterprises (SMEs) when expanding to Asia by using qualitative research. Through a country selection process, the Field Lab identifies potential target countries. Malaysia, Thailand, and Indonesia are evaluated as the most attractive Asian markets. Based on the analysis of political, economic, and socio-cultural conditions, the healthcare system and pharmaceutical industry, Malaysia identifies as the best country to enter for German pharmaceutical SMEs. Strategic recommendations for Malaysia are formulated through a 5-phase action plan for the short-term, followed by medium- and long-term recommendations for Thailand and Indonesia, respectively.

Keywords

Internationalization Strategy, Market Selection, Market Conditions, Pharmaceutical Industry, German SMEs, Southeast Asia, Malaysia, Thailand, Indonesia

This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences DataLab, Project 22209), POR Lisboa (LISBOA-01-0145-FEDER-007722 and Social Sciences DataLab, Project 22209) and POR Norte (Social Sciences DataLab, Project 22209).

TABLE OF CONTENTS^{1,2}

1	Introduction	3
2	Literature Review	4
2.1	Introduction to the Pharmaceutical Industry	4
2.2	Current Market Conditions and Challenges in the German Pharmaceutical Industry	6
2.3	Business Opportunities in Asia	9
2.4	Business Opportunities in the Asian Pharmaceutical Industry	11
3	Country Selection Process	12
3.1	Quantitative Selection	12
3.2	Qualitative Selection and Decision Making	16
4	Research Methodology	17
5	Analysis of the Pharmaceutical Industry in Malaysia, Thailand and Indonesia	20
5.1	A. Hanfmann – Examination of the Pharmaceutical Industry in Malaysia	20
5.1.1	Political, Economic and Socio-Cultural Conditions	20
5.1.2	Healthcare Sector Overview	21
5.1.3	Analysis of the Pharmaceutical Industry	23
5.1.4	Qualitative Research Findings	27
6	Overarching Qualitative Research Findings regarding an Internationalization to MIT	33
6.1	German Expertise	33
6.2	Market Entry Conditions	33
6.3	Opportunities and Risks for German SMEs	34
7	Discussion	35
8	Strategic Guidelines and Recommendations	41
9	Conclusion	46
10	Limitations and Future Research	47
11	References	48
12	Appendices	53

¹ All parts that are not specifically marked by a student's name are group parts.

² List of Figures and List of Tables can be found in Appendix 1; List of Abbreviations can be found in Appendix 2.

1 Introduction

“Medicines [...] are one of the building blocks of a health system. Without them, it is impossible to achieve desirable health outcomes for individual patients and communities.” (WHO 2018, 2). Pharmaceutical companies play a crucial role in the global advancement of healthcare services, providing essential treatments, creating jobs, and boosting the global economy. Once more, the COVID-19 pandemic put the pharmaceutical market at the center of public attention. Fueled by an aging population and new product launches, it experienced significant growth in the past decades, resulting in worldwide revenues of \$1.4tn USD (Statista 2022a). German pharmaceutical companies contribute significantly to this growth and distinguish Germany as an important location in the industry (Mikulic 2021). Particularly, German small and medium-sized enterprises (SMEs) stand out due to their high specialization of products and services and their innovative strength (BMWK 2019). As growth opportunities in Germany diminish, identifying and entering new markets is of utmost importance for German players. Due to their growth potential, emerging Asian markets offer excellent opportunities for expansion (EFPIA 2022, 4). However, the diversity and heterogeneity of Asian countries underline the relevance of determining which countries are best suited for expansion. Consequently, this paper aims to analyze the business opportunities and risks for German pharmaceutical SMEs in Asia. The objective is to find a region where three relevant and potentially suitable countries can be analyzed in detail to provide German SMEs with theoretical and practical recommendations for market entry. Within the scope of this work, only pharmaceutical manufacturing is considered.

This paper starts with a literature review of the pharmaceutical industry with a particular emphasis on Germany and the corresponding business opportunities in Asia. Subsequently, the selection process to identify the most relevant Asian countries is explained in detail, presenting the three potential expansion markets as output. Hereafter, the research methodology is outlined, followed by an in-depth examination of the three countries considering a political, economic and socio-cultural analysis, healthcare and pharmaceutical industry analysis as well

as qualitative findings from expert interviews. In addition to these country-specific findings, overarching findings are presented. Finally, the paper ends with a discussion, strategic recommendations, a conclusion as well as limitations and a future outlook.

2 Literature Review

The literature review introduces the pharmaceutical industry in general and in Germany and elaborates on the business opportunities in Asia and the Asian pharmaceutical industry.

2.1 Introduction to the Pharmaceutical Industry

In broad terms, the expression “pharmaceuticals” refers to manufactured products generated by a specific industry across which companies compete in various business sectors for the commercially motivated research, development, production, and distribution of medications. The terms “medication”, “medicine”, “pharmaceutical”, and “drug” are used interchangeably. (Taylor 2015, 1). One can mainly differentiate between two types of pharmaceuticals: “prescription pharmaceuticals” that are prescribed by a doctor and are intended to be used by one person as well as “over-the-counter pharmaceuticals” that do not require a doctor’s prescription and can be purchased at pharmacies, drug stores as well as online (US FDA 2017).

Pharmaceuticals have historically played a significant role in human development and nowadays have become a fundamental component of the global healthcare system. The pharmaceutical industry is crucial to the development of healthy and productive nations due to its direct connection to human welfare and well-being. Nowadays, the industry is one of the world’s largest and fastest expanding (SESRIC 2009, 2).

However, the pharmaceutical industry is a complex system marked by several striking characteristics that set it apart from the common ground of knowledge about the industry. Even though the industry has made a significant contribution to human wellbeing and welfare, it is still regularly identified by the public as one of the least trusted industries. Despite the fact that the largest pharmaceutical firms rightly promote themselves as research-based organizations, many customers remain suspicious (Hester and Harrison 2016, 1–2).

Conventional pharmaceuticals can be classified into two types: firstly, there are original drugs, also known as patented or innovator drugs, which are pharmaceuticals that have undergone extensive research and development (R&D). Manufacturers of original pharmaceuticals are usually granted a 20-year patent; afterwards, other manufacturers are permitted to use those formulae as well. Secondly, generic drugs are imitations of original drugs, often manufactured under a trademark or brand name but lacking patent protection. Generic medications frequently contain active ingredients that are identical to those found in original drugs whose patents have expired. Because generic pharmaceuticals generally not require expensive inputs or costly R&D and clinical studies, the manufacturing costs are typically cheaper than those of original drugs (Tunpaiboon 2019, 1).

The pharmaceutical industry is relatively Intellectual Property (IP) intensive, as measured by trademark and patent intensity. Accounting for around 5% of all global trademark applications registered annually, the pharmaceutical industry is the 4th most IP intense industry according to the Nice product classification. The industry is determined to maintain its IP rights since developing new products is a costly process that is critical to long-term success (OECD and EU IP Office 2020, 25). The high level of investment in R&D, which amounts to \$238bn USD in 2022 and is projected to reach \$285bn USD in 2028, reflects the cost and relevance of new products (Statista 2022c). Furthermore, the R&D process is lengthy, as developing a new medication or vaccine might take 10 to 15 years (OECD and EU IP Office 2020, 25).

The pharmaceutical industry is characterized by several stakeholders competing to accomplish their interests (Dickov, Mitrovic, and Kuzman 2011, 2). Although the industry is in public view dominated by a small number of very large multinational corporations (MNCs) like Pfizer, Roche, and Novartis (collectively known as “Big Pharma”), these well-known companies only resemble the tip of the iceberg. They account for around 40% of the market financially; nevertheless, they represent just a small portion of the overall industry, as more

than 90% of pharmaceutical companies are generic manufacturers that remain relatively unknown to the public. As a result, most medications supplied are manufactured by these generic companies (Taylor 2015, 8–9).

As the link between the laboratory and the marketplace, the pharmaceutical supply chain is complex. It encompasses all organizational, operational, and value-added operations from new product development through active pharmaceutical ingredient manufacturing and secondary manufacturing, including packaging to distribution via a wholesaler, retail pharmacy or hospital, and ultimately, the patient (see Appendix 3) (PwC 2020, 3).

2.2 Current Market Conditions and Challenges in the German Pharmaceutical Industry

Germany is one of the world's most developed nations. It has the largest economy and consumer market in the European Union (EU), with approximately 83 million residents (World Bank 2021k). After the United States (US), China, and Japan, Germany has the fourth largest economy in the world (KPMG 2022). Moreover, Germany is the third largest exporter and importer worldwide, with export levels of \$2tn USD and import levels of \$1.8tn USD in 2021 (World Bank 2021g; 2021d). Its most important trading partners are countries within the EU which account for 68.2% of exports and 67.8% of imports (BMWK 2022a). In 2021, the automotive industry was Germany's largest sector, followed by the mechanical engineering, chemical and pharmaceutical, and electrical engineering sector (Rudnicka 2022). In an international comparison, with revenues of \$57bn USD in 2020 (see Appendix 4), Germany is the fourth largest pharmaceutical market after the US, China, and Japan (Mikulic 2021). This underlines the relevance of Germany as a pharmaceutical location and the expertise available. Prof. Dr. Hagen Pfundner, Management Board of Roche Pharma AG, echoes this insight by stating: *"Germany is one of the most developed healthcare markets in the world and a strategic gateway to the EU single market for international companies."* (Albrecht and Kemper 2021, 2). Figure 1 displays key statistics of the pharmaceutical industry in Germany. In 2021,

revenues in the German pharmaceutical industry increased by 7.3%, reaching €53.6bn EUR (IQVIA 2022, 7).




Figure 1: German Pharmaceutical Industry Overview, Source: Own illustration based on (IQVIA 2022, 7)¹, (BPI 2021, 6–7)², (ZEW 2021)³

Pharmaceutical companies in Germany benefit from a strong infrastructure and an aging population which increases demand for pharmaceutical products (Vfa 2022). Several factors lead to Germany being a significant pharmaceutical market. First, the geographical proximity to other well-developed industries, such as mechanical engineering, has a beneficial impact. It enables an intensive exchange in the planning of production plants and a faster procurement of replacements in the event of technical problems (Vfa 2022).

Second, the workforce of the pharmaceutical industry in Germany is highly qualified. It is crucial to employ highly skilled professionals to manufacture pharmaceutical products efficiently. Also, digitization increases the demand for specialists in the design of digitized production processes and data analytics. Both conditions are thoroughly addressed when looking at Germany and are made possible by the strong training standards (Vfa 2022).

Third, the German pharmaceutical industry is one of the most productive, research-intensive, and innovative sectors. In recent years, spending on R&D has continuously increased. In 2015, pharmaceutical companies spent around €6bn EUR on R&D, while in 2019, spending amounted to €8.5bn EUR, representing 42% growth in four years (Stifterverband 2021, 5).

Moreover, nearly 20% of pharmaceutical companies' sales were reinvested in product innovation, which are peak figures compared to all other industrial sectors (ZEW 2021).

Role of SMEs

There is no universal definition of SMEs. The European Commission defines SMEs as firms with less than 250 employees or generating up to €500mn EUR in annual turnover (European Commission 2020, 3). In addition, the German Federal Ministry for Economic Affairs and Climate Action classifies SMEs as companies with annual revenues of up to €50mn EUR or less than 500 employees (BMWK 2022b). The SME sector is extremely varied, encompassing large family businesses, craft enterprises, startups, and global market leaders. SMEs are an essential part of the German economy, making up more than 99% of all businesses and accounting for 58.5% of jobs (BMWK 2019). In fact, the outstanding export performance is primarily due to SMEs, which contribute to around 70% of total exports (Simon 2016).

Moreover, Germany has the highest number of small and mid-sized market leaders worldwide, totaling 1,307 (Simon 2016). These companies are called “hidden champions” and represent companies that offer highly specialized products or services and are a driver of innovation and technology. In 2014, almost half of the German SMEs introduced new products or services to the market, in contrast to the EU average of around 30% (BMWK 2019). Furthermore, an essential aspect of German hidden champions is their tendency to keep production and R&D processes within the company rather than transferring their value to other companies. Thus, they prefer exporting or installing subsidiaries rather than subcontracting overseas (Herr and Nettekoven 2018, 21).

Challenges

Although the German pharmaceutical market experiences several challenges, only the one of limited growth opportunities will be addressed to remain within the focus and scope of this paper. The German pharmaceutical market is growing, however, at a different pace than other

markets. Looking at the development from 2016 to 2021, the Chinese and Indian pharmaceutical markets grew by 6.7% and 11.8%, respectively. In contrast, the top five EU markets, France, Germany, Italy, Spain, and the UK, recorded significantly lower average market growth of 5.8% (EFPIA 2022, 4). Furthermore, by 2030, the Asian share of global GDP will reach 52%, three times Europe's share of only 17% (World Economics 2022).

For the reasons mentioned above, German SMEs need to explore new markets in addition to the less attractive European expansion opportunities. Therefore, the focus of this paper is to analyze the business opportunities for German SMEs in different Asian countries.

2.3 Business Opportunities in Asia

In recent decades, Asia has experienced a rapid growth transformation in various economic and societal aspects. Table 1 shows the economic growth of the different Asian regions for 2022 and prospects for 2023 (Asian Development Bank 2022a).

Region	Economic Growth in 2022	Economic Growth in 2023
East Asia	4.7%	4.5%
Southeast Asia	4.9%	5.2%
South Asia	7.0%	7.4%
Central Asia	3.6%	4.0%

Table 1: Economic Growth in Asia, Source: Own illustration based on (Asian Development Bank 2022a)

One powerful driver of economic growth is trade. For decades, Asia's continuous rise of GDP was complemented by a steady implementation of trade openness measures. The liberalization of foreign trade and foreign direct investment (FDI) as well as the reduction of import tariffs lead to a higher share of trade in domestic GDP (Kawai and Wignaraja 2014, 3).

Asia's integration into global value chains sparks welfare gains, increased productivity and stabilized cooperation (UNESCAP 2015, 103). Intraregional trade makes up 52% of the total Asian trade (Tonby et al. 2019, 7). Its rapid rise strengthens the relation among the Asian nations and serves as a protection against global economic and trade policy uncertainty (Asian Development Bank 2017). The establishment of several free trade agreements like the Association of Southeast Asian Nations (ASEAN), Transpacific Partnership (TPP), and

Regional Comprehensive Economic Partnership (RCEP) are effective for Asia's significant cross-border and intraregional trade activities (Kawai and Wignaraja 2014, 23–24).




Figure 2: Free Trade Agreements in Asia, Source: Own illustration based on (Carlson et al. 2021, 110)

The rising middle class is one apparent side effect of the rapidly evolving economies in Asian nations, with considerable size and unprecedented growth. Asia's middle class is projected to grow from around 2 billion people in 2020 to an estimated 3.5 billion people by 2030 (Statista 2020). Ogilvy's Velocity 12 ranking identifies the twelve fastest growing middle-class markets which account for half of the world's population and 73% (Ogilvy 2016, 26) of the global middle class. With eight out of twelve countries being Asian (India, China, Pakistan, Indonesia, Bangladesh, Philippines, Vietnam and Myanmar), the significance and pace of the continent's growth is highlighted (Ogilvy 2016).

Hence, millions of Asian inhabitants were lifted out of severe poverty over the last decades. The poverty reduction creates improved living standards, expanding spending power and an overall higher quality of life for all socioeconomic groups (Tonby et al. 2019, 3).

Another prevalent trend that is reshaping Asia is urbanization. The increasing concentration of residents in urban cities, in particular from the middle-class, provides increased access to education and to public health provision. Therefore, rapid urbanization transforms big cities into sources of innovation and wealth generation (Tonby et al. 2019, 3).

The combination of Asia's incomparable market size (Statista 2020), dynamic nature and pace of economic growth creates a plethora of business opportunities for foreign businesses that plan to expand to new markets (Greenbaum 2018, 30–31).

2.4 Business Opportunities in the Asian Pharmaceutical Industry

The COVID-19 pandemic poses the most devastating worldwide challenge to the healthcare sector of this century. The whole continent of Asia has been extremely affected by COVID-19 (Nuruzzaman and Tateno 2021, 6) and experienced severe volatility and instability within the nations' healthcare systems. Various economic operations were disrupted due to the implementation of country-wide lockdowns and border restrictions to prevent further COVID-19 spreading (Asian Development Bank 2022b, ix). With the exception of China, which continues to pursue “zero COVID policies” (Song 2022), the Asian region is currently in a post-pandemic recovery. Its pace in the healthcare sector is remarkable as it is growing back even faster than the economies (OECD and WHO 2020).

As Asia has evolved into a crucial element of the global pharmaceutical ecosystem, multiple drivers speed up the expansion of the pharmaceutical industry (Liu 2022, 10). A key factor for Asia's current significance and future growth potential in the pharmaceutical market is its aging population. The enormous pace of aging in Asian countries can be attributed to declining birth rates and rising life expectancy due to improved living standards and increased access to healthcare (UNESCAP 2017, 4–5). By 2030, more than 60% of the world's population over 65 years is expected to reside in Asia. The number of people aged 65+ in Asia will increase from 365 million in 2017 to more than 520 million in 2027, making it the largest and fastest-growing market globally (Deloitte 2017).

Moreover, changes in lifestyle and dietary habits, such as less physical exercise, rising consumption of high-cholesterol food, alcoholic beverages and tobacco are contributing to an increase in noncommunicable diseases (NCDs) among Asian nations. NCDs include cancer, metabolic, cardiovascular and mental health illnesses (WHO 2020).

Although Asia has some competitive pharmaceutical markets, there are still a lot of unfulfilled healthcare needs in the rising markets of the region. The combination of the growing demand and the partially deficient offerings creates a target-rich setting, allowing businesses to concurrently address crucial medical needs and capitalizing on the enormous investment potential in the pharmaceutical industry (The Economist 2018, 3–8).

3 Country Selection Process

To narrow down the potential expansion markets for German pharmaceutical SMEs in Asia that warrant an in-depth examination, a country selection process with both a quantitative and qualitative selection part is performed.

3.1 Quantitative Selection

To identify a selection of Asian countries that show the highest market potential for German pharmaceutical SMEs based on available data, a quantitative country selection is conducted³. It consists of a country ranking and a country clustering process based on all Asian countries. In a first step, only countries that currently find themselves in highly critical political situations (North Korea, Syria, Afghanistan) have been excluded.

In both analyses, 28 variables from 11 different dimensions were considered, each with a specific attributed weight, summing up to 100% (see Figure 3). As shown in Figure 3, the 11 dimensions are organized in (1) Market Size, (2) Market Intensity, (3) Market Growth Rate, (4) Market Receptivity, (5) Standard of Living, (6) Digital Affinity, (7) Ease of Doing Business, (8) Country Risk, (9) Economic Freedom, (10) Cultural Distance and (11) Healthcare Specifics.

³ The data can be found in the “Country Selection” Excel file as well as the “Output Country Clustering” SPSS file.

Market Receptivity					Economic Freedom		Cultural Distance	Ease of Doing Business
Consumer Price Index	Trade (% of GDP)	Net Trade in Goods (BoP, current US\$)	Logistics Performance Index (1=low to 5=high)	Foreign Direct Investment, Net Inflows (BoP, current US\$)	Economic Freedom Index	Political Freedom Index	Cultural Distance to Germany	Ease of Doing Business (0 = Lowest Performance to 100 = Best Performance)
1%	4%	2%	2%	5%	2%	2%	2%	12%

Market Size			Digital Affinity	Market Intensity		Market Growth Rate		
Population Ages 65 and Above (% of Total Population)	Urban Population (% of Total Population)	Population Density	Individuals Using the Internet (% of population)	GDP per Capita	Adjusted Net National Income per Capita	Annual Population Growth	Annual Urban Population Growth	Annual GDP per Capita Growth
2%	2%	1%	2%	2%	1%	9%	9%	9%

Country Risk				Healthcare Specifics				Standard of Living	
Business Environment Risk*	Political Risk Rating	Country Risk	Competitiveness Rank	Domestic General Government Health Expenditure (% of GDP)	Current Health Expenditure per Capita	Current Health Expenditure (% of GDP)	Burden of Disease	Life Expectancy	Unemployment Rate (% of Workforce)
2%	2%	2%	2%	6%	8%	7%	2%	1%	3%

Figure 3: Country Selection Dimensions and Variables, Source: Own illustration based on Country Selection Excel file

General as well as industry-specific dimensions have been considered. They cover economic, market related as well as political and cultural data. By taking indicators from 11 different dimensions into consideration, the analysis becomes holistic and objective to determine non-biased results. In particular, the dimensions (3) Market Growth Rate, (7) Ease of Doing Business, and (11) Healthcare Specifics are considered most important. In sum, those three dimensions account for 60% of the weighting. In the following, the variables assigned to those are described. A description and reasoning of all 28 variables can be found in Appendix 5.

Dimensions & Total Weight	According Variables & Weight	Description and Reasoning
Market Growth Rate: 25.5%	- Annual Population Growth: 8.5% - Annual Urban Population Growth: 8.5% - Annual GDP per Capita Growth: 8.5%	As it will be interesting for German SMEs to expand to growing and dynamically evolving markets, population as well as GDP per capita growth is considered highly relevant.
Ease of Doing Business: 11.5%	Ease of Doing Business: 11.5%	Since the Ease of Doing Business Index aggregates ten areas of business regulation when starting or operating a local business, it is considered the most important variable.

Healthcare Specific Variables: 23%	▪ Current Health Expenditure per Capita: 8% ▪ Current Health Expenditure as % of GDP: 7% ▪ Domestic General Government Health Expenditure as % of GDP: 6% ▪ Burden of Disease: 2%	Relative health expenditure data gives insights about the healthcare industry development status of a country and thus of high importance for the pharmaceutical industry. Burden of Disease measures the impact of living with illness and injury and dying prematurely and thus is another important healthcare specific variable.
---	--	--

Table 2: Selected Dimension and Variable Description and Reasoning, Sources in chronological order: (World Bank 2022b; 2022c; 2021f; 2019f; 2019c; 2019a; 2019e; Roser, Ritchie, and Spooner 2021)

Country Ranking

A country ranking is performed and results in an index that is an aggregate measure of attractiveness and therefore used at the preliminary market assessment stage. To prevent scale effects and artificial weighting, the raw data of the individual variables within each dimension is standardized into z-scores. The data is transformed to a 1-100 scale to enable easier interpretation (see Appendix 6). In this process, an inverse standardization formula was applied to 10 of the 28 variables, as for those, a higher score signifies a lower potential for German pharmaceutical SMEs (see Appendix 7). The variables being inversed are (1) Foreign Direct Investment, Net Inflows, (2) Unemployment Rate as % of Workforce, (3) Business Environment Risk, (4) Political Risk Rating, (5) Country Risk, (6) Competitiveness Rank, (7) Cultural Distance, (8) Domestic General Government Health Expenditure as % of GDP, (9) Current Health Expenditure per Capita as well as (10) Current Health Expenditure as % of GDP. Whereas for variables (2) to (7) the inversion can be considered evident, particular explanation is needed for the inversion of variables (1), (8), (9), and (10). Although, in general, a high score for those variables signifies a positive status, in the case of investigating market attractiveness for German pharmaceutical SMEs, in the present paper it is considered advantageous if these variables are rather at an infancy or developing stage instead of a highly developed stage.

To reach the final market opportunity score of each country, the scores of the variables are combined with the corresponding weights. In the obtained ranking, it was possible to identify the ten markets with the highest potential for German pharmaceutical SMEs, namely:

1	Malaysia	6	Kazakhstan
2	United Arab Emirates	7	Thailand
3	Bahrain	8	Brunei Darussalam
4	Qatar	9	Indonesia
5	Oman	10	Singapore

Figure 4: Country Ranking – Top 10 Countries

Country Clustering

To further specify the results of the country ranking, a country clustering was performed. The focus of the clustering is to identify groups of countries with similar political, economic, and socio-cultural conditions. It is based on the variables of the three dimensions, that were considered most important in the country ranking: (3) Market Growth Rate, (7) Ease of Doing Business, and (11) Healthcare Specific Variables⁴. Although taking into consideration all the 11 dimensions would enable achieving a more holistic perspective, this would implicate a limitation in terms of specification. A hierarchical country clustering according to the Ward's method and z-score standardization has been performed using SPSS, resulting in a dendrogram (see Appendix 8). The dendrogram illustrates the countries' hierarchical relationship and classifies them into clusters. Several clusters have been formed according to a rescaled distance of three. The clusters are shown in Figure 5 below.

Cluster 1		Cluster 2		Cluster 3		Cluster 4		Cluster 5		Cluster 6		Cluster 11	
Philippines	15	Bangladesh	31	Lebanon	44	China	25	Maldives	41	Germany	40	Singapore	10
Sri Lanka	34	Lao PDR	30	Myanmar	43	Turkiye	14			Japan	36		
Kyrgyz Republic	26	Cambodia	33			Georgia	22						
Mongolia	20	Iraq	39			Russia	29						
Bhutan	24	Timor Leste	42			Armenia	37						
Vietnam	18					Iran	38						
India	11					Jordan	35						
Indonesia	9					Kuwait	27						
Bahrain	3					Saudi Arabia	19						
Oman	5					Cyprus	21						
Nepal	23					Israel	13						
Pakistan	28					Korea, Rep.	16						
Tajikistan	32												
Uzbekistan	17												
Brunei Darussalam	8												
Qatar	4												
Kazakhstan	6												
Malaysia	1												
Azerbaijan	12												
Thailand	7												
United Arab Emirates	2												
Average	15		35		44		25		41		38		10
<=10 >10 >20													

Figure 5: Country Clusters based on the Dendrogram, Source: Own illustration based on the "Output Country Clustering" SPSS file, can be found in the Country Selection Excel file

⁴ Only those variables weighted above average (3.6%) have been considered, excluding the variable "Burden of Disease", weighted with 2%.

3.2 Qualitative Selection and Decision Making

As the ranking results are confirmed by the clustering results, it can be said that the ten countries identified indeed offer the highest potential for German pharmaceutical SMEs in Asia. To reduce the number of countries that warrant in-depth investigation as potential target markets to start off in, the attractiveness of the top-ranked countries is evaluated by applying the following qualitative criteria.

1. Market Size

To ensure the market size in the expansion country being large enough, a critical value in terms of population size is set to five million. This criterium excludes Bahrain (1.75 million), Qatar (2.93 million), and Brunei Darussalam (441,534) (World Bank 2021i; 2021m; 2021j).

2. Level of Development

To ensure an expansion to a country that is at a developing rather than developed economic stage and thus has a lot of growth potential, highly developed economies are not considered preferable. The United Arab Emirates, Oman as well as Singapore are classified as “High-Income Economies” (GNI per capita of \$13,205 or more), while the remaining countries are classified as “Lower-Middle-Income Economies” or “Upper-Middle-Income Economies” (World Bank 2022d). Thus, the United Arab Emirates, Oman and Singapore are excluded.

3. Potential Ease of Expansion

An internationalization to a country being part of a region is considered advantageous in terms of future expansion opportunities due to potential regulatory agreements (e.g. free trade agreements) expanding the potential market size. Considering Malaysia, Thailand, and Indonesia being part of the ASEAN, RCEP and APEC agreements and summing up to a total market size of 379,087 million (population-wise), those three countries offer high expansion potential (World Bank 2021h; Holloway 2005a, 3–14). Thus, starting off the internationalization in one of those countries could be a door-opener to the further Southeast Asian (SEA) region. Especially when comparing that value to the market size of Kazakhstan

being 19 million, it becomes evident that the growth potential in this market is more limited (World Bank 2021l).

Due to the strategic advantages in terms of market size, level of development as well as future growth and expansion potential, it was decided to further analyze Malaysia, Thailand and Indonesia⁵ in-depth. Figure 6 summarizes and visualizes the country selection process.




Figure 6: Country Selection Funnel, Source: Own illustration based on filters used for country selection

4 Research Methodology

In the following chapter, the research process will be elaborated on.

Research Approach

As part of this paper, both primary and secondary data has been gathered to ensure accurate results. Data was collected through three approaches: (1) Literature Review, (2) Qualitative Expert Interview, and (3) Quantitative Survey. This mixed methods approach was adopted to provide various levels of detail and to examine the research topic from different angles due to the complexity of the research question (Ochieng 2009). First, secondary data was researched from multiple sources such as company reports, academic journals, books, online databases, and websites. Second, semi-structured qualitative expert interviews were conducted with different pharmaceutical industry stakeholders in Germany and Asia to gain insights into business opportunities and risks from an executive perspective. Third, a quantitative survey was

⁵

Henceforth, the abbreviation MIT is used when referring to the three countries Malaysia, Thailand and Indonesia at the same time.

performed to complement the analysis and get insights into the perception of the pharmaceutical industry in MIT, including consumers' perceptions. The surveys' main goal was to analyze the trustworthiness of foreign vs. local pharmaceutical companies in MIT (see questionnaire in Appendix 9). It was distributed via LinkedIn, Facebook groups, and experts, achieving 2029 impressions as of 24.11.2022. However, with 23 answers in total, the response rate of 1.13% is too low for further analysis due to a possible sampling bias. Therefore, only qualitative research is utilized.

Recruitment of Participants and Interview Process

For the expert interviews, the semi-structured method was chosen for its flexibility, open-ended nature, and scope for creativity. This interview type includes an interview guide with a list of questions or themes that do not have to be followed strictly. In contrast, the goal is to investigate the research area by gathering comparable information from every participant (Holloway 2005b, 3–14). Participants were recruited and contacted through online research via LinkedIn and E-Mail or through personal contacts. A total of 128 stakeholders working in the healthcare and pharmaceutical business were contacted. The focus was both on stakeholders from German pharmaceutical businesses (companies of different sizes) to ask about their expansion experiences in SEA and on stakeholders from pharmaceutical businesses in MIT. Further, consultants with extensive knowledge of the pharmaceutical business in Germany and SEA have been contacted to get a more comprehensive picture of the pharmaceutical industry and the business opportunities in this region. The aim was to recruit at least three experts per country to gain valuable and detailed insights into the industry in each country, including the opportunities and risks for German SMEs. It was important that the stakeholders have at least five years of experience to ensure sufficient industry knowledge. Therefore, mainly senior executives with extensive knowledge of the pharmaceutical industry have been interviewed.

Further information and reasoning regarding the experts are provided in Appendix 10, including a link to all interview transcripts.

A total of 18 stakeholders responded to the requests. Out of this number, three did not reply to schedule the interview, leaving 15 stakeholders. The interviews were conducted via video call on the platforms Microsoft Teams and Zoom between October 15th and November 7th, 2022. Interviews were held in English and lasted between 30 to 40 minutes. Notes were taken, supplemented by voice recording, which enabled the transcription of the interviews with the online transcription software Otter.ai.

Data Analysis Approach

Before conducting the interviews, a discussion guide was created. This guide includes two sub-guides, one for stakeholders working in Germany and one for stakeholders working in the SEA region (see Appendix 11). After transcribing all interviews, “coding” words, patterns, and similar responses have been collected to identify common topics and ideas. As a result, the following overarching themes have been established: (1) Overview of the Pharmaceutical Industry in MIT, (2) Market Entry Conditions, (3) Opportunities and Risks. Findings for each country and overarching findings regarding German pharmaceutical SMEs and universal MIT insights are presented in the following.

5 Analysis of the Pharmaceutical Industry in Malaysia, Thailand and Indonesia

The following chapter analyzes the pharmaceutical industries of Malaysia, Thailand and Indonesia separately. It consists of insights from literature as well as qualitative research.

5.1 A. Hanfmann – Examination of the Pharmaceutical Industry in Malaysia

The following chapter examines the pharmaceutical industry in Malaysia based on a political, economic, socio-cultural, and market entry conditions analysis.

5.1.1 Political, Economic and Socio-Cultural Conditions

Sharing its borders with Singapore, Thailand, Indonesia and Brunei, Malaysia consists of 13 states and encompasses two regions, Peninsular Malaysia (except for Singapore) and Borneo's East Malaysia (Witt 2021, 1).

Malaysia is a federal constitutional monarchy, where legislative power rests with both the federal parliament and the state parliaments. Malaysia has well-developed foreign relations through bilateral agreements. It is a founding member of ASEAN, APEC as well as RCEP (Witt 2021, 3). Malaysia's political risk is rated as low with 2 out of 7 points, with 7 indicating the nations where political events are most likely to result in intense risks (Credendo 2022). The Corruption Perception Index ranks the country 62nd place out of 180 countries. In SEA, only Singapore is ranked lower with rank four (Transparency International 2021).

With a GDP of \$372.7bn USD in 2021 and being considered one of the most developed developing nations in the world, Malaysia is currently categorized as an upper-middle income nation by the World Bank (World Bank 2022a; 2022d). It has seen steady development over the last five years, with an average GDP growth of 2.52% each year. (PwC 2022a, 6). Today, the nation's standards of living is among the highest in SEA and, based on the IMD World Competitiveness Ranking 2022, Malaysia is considered as the second most developed and competitive country in SEA, ranking 32nd globally (Switzerland Global Enterprise 2021, 7). At the same time, the country offers the lowest cost of living among the SEA countries (PwC 2022a, 8). According to the Global Opportunity Index 2022 report, Malaysia ranks 1st in emerging SEA for foreign investment, significantly outperforming the emerging markets and

developing economies benchmark. There is a large and diverse presence of foreign companies with a cumulative investment (Foreign Direct Investment (FDI) stock) of \$189bn USD in 2021, meaning that the country is very open to foreign investments (PwC 2022a, 8).

In 2021, there were 32.57 million people living in Malaysia. With 22.6% of the population living in rural regions and 77.4% in urban areas, Malaysia is one of the most urbanized nations in SEA. Malaysia's population is unequally distributed between Peninsular where the vast majority is living, and East Malaysia (Switzerland Global Enterprise 2021, 8). It is anticipated that by 2035, Malaysia will have an aging population accounting for 15% of the nation's total population (Switzerland Global Enterprise 2021, 13). Malaysia's society is hierarchical and collectivist (Witt 2021, 4). Although Malay is Malaysia's official language, as a former British colony English is commonly spoken, especially in business (PwC 2022a, 6).

5.1.2 Healthcare Sector Overview

In recent decades, Malaysia has made great gains in its healthcare development. The current life expectancy is above that of upper middle-income countries (78 years for women, 74 years for men) (World Bank 2020b; 2020a) with per capita healthcare spending being \$437 USD in 2019, ranging among the highest in the region (World Bank 2019d). From 2014 to 2019, Malaysia's healthcare spending as a share of national GDP remained largely stable, ranging between 3.7% and 3.8% (World Bank 2019b). Appendix 12 displays further numbers. In Figure 7, the evolution of health expenditure from 2009 to 2019 is visualized.




Figure 7: Health Expenditure in Malaysia, Sources: Own illustration based on (World Bank 2019d; 2019b)

As healthcare spending accounts for 4.5% of GDP in 2021, the government has designated healthcare as one of the National Key Economic Areas under the Economic Transformation Program to lead Malaysia to high-income status. Although the national spending on healthcare has already increased more than two and a half times during the last two decades (CEDAR 2018, 1), the demand for quality healthcare continues to rise in Malaysia with rising consumer awareness, the growing population, and a longer life expectation, increasing the government's investment in healthcare development in terms of clinical research, infrastructure, and services (MIDA 2020, 3).

Malaysia has a two-tiered healthcare system that consists of a universal public healthcare system as well as a coexisting private healthcare sector that is mostly responsible for delivering specialized services. In the public sector, which is financed through general income taxes by Malaysian citizens, patients only have to pay nominal fees. However, approximately 65% of the population is served by the public sector, while only 45% of registered doctors and even fewer specialists do so. Hence, the private sector contributes significantly to the provision of specialized services (Switzerland Global Enterprise 2021, 5).

Due to its superior infrastructure, trained workforce and high-quality services, Malaysia has established a global reputation for having a high-performing health system. However, a variety of interconnected challenges, including a fast growing aging population and an increase in NCDs are posing difficulties for the system (Switzerland Global Enterprise 2021, 13).

After Thailand, Malaysia has emerged as the second most important hub for medical tourism in SEA. In particular, Malaysia promotes itself as the “Cardiology and Fertility Hub of Asia” (Switzerland Global Enterprise 2021, 14). Malaysia's medical tourism market is expected to grow at around 30% annually for the next years and reach \$3.06bn USD by 2024 (CEDAR 2018, 2). Thus, the government actively promotes Malaysia as a health tourism destination to capitalize on the lucrative and expanding international market (APO 2013, 19).

The country undergoes an epidemiological transition, with the leading causes of death moving from communicable to NCDs. This transformation is more progressed than in neighboring nations, but less advanced than in Singapore (APO 2013, 8). This substantial increase in NCDs in recent decades owes to the prevalence of unhealthy diets, low physical activity, and the consumption of cigarettes and alcohol (CEDAR 2018, 1). Currently, they are responsible for 70% of all deaths, an increase of around 16% compared to 2011 (Institute for Public Health 2017, 9). Malaysia has one of the highest rates of diabetes in the Asia-Pacific region, with about one-fifth of its population suffering from the condition in 2017 (CEDAR 2018, 1). The top five burden of disease categories, referring to the years lost due to mortality and morbidity, are dominated by NCDs, amounted to 2.4 disability adjusted life years in 2021 (Institute for Public Health 2017, 9).

5.1.3 Analysis of the Pharmaceutical Industry

The following chapter provides an in-depth analysis of the pharmaceutical industry in Malaysia.

5.1.3.1 Status Quo

In SEA, the Malaysian pharmaceutical industry is situated as the fourth largest with an estimated industry value of approximately \$3.82bn USD⁶ in 2021 (GlobalData 2022b, 5). The industry is predicted to grow at a rate of 10% per year, more than double the Asia-Pacific average (CEDAR 2018, 1). Regarding per capita expenditure on pharmaceutical products, Malaysia amounted to approximately \$200 USD in 2020, ranging second in SEA, however the value is significantly lower than the one of the leading nation Thailand (\$600 USD in 2020) (Statista 2022b). Pharmaceuticals get distributed to the end-consumer through various channels. On the one hand, hospitals account for nearly half of the domestic distribution, with 18% being distributed via private hospitals and 31% being distributed via public hospitals. On the other hand, community pharmacies account for 36% of the distribution and general practitioners represent 15% of the domestic distribution (Pharmaceutical Association of Malaysia 2018, 9).

⁶ All local currency values from the original source were converted to US Dollars according to the exchange rate of 22.11.2022.

Prescription medications dominate the market, accounting for around 60% of the market share by value (Hassali et al. 2015, 171).

Government expenditure and legislative measures have supported the growth of Malaysia's pharmaceutical markets with pharmaceuticals receiving special attention in healthcare being classified as one of the country's 12 National Key Economic Areas. Malaysia offers incentives to international pharmaceutical businesses to enhance investments and cooperation especially in innovative and high-end pharmaceutical products (CEDAR 2018, 2).

5.1.3.2 Market Entry Conditions

Competitive Landscape

Malaysia's pharmaceutical manufacturing business is rapidly expanding. It is dominated by two types of key market players: local firms and research-based multinationals, each with its own set of priorities and objectives. Around two-thirds of Malaysia's approximately 250 registered local manufacturing firms are focusing on traditional and herbal medicines, with the remaining third mostly producing generics. As a result, there is a high demand in Malaysia for branded and high-end pharmaceutical items from multinational corporations (also known as innovators), to ensure that Malaysians have access to new and innovative drugs and treatments that are internationally tested and quality-assured (CEDAR 2018, 1–2; Pharmaceutical Association of Malaysia 2018, 6).

Pharmaniaga Manufacturing Berhad, Hovid Berhad and Duopharma Biotech Berhad are among the significant local companies. These businesses mostly manufacture generic pharmaceuticals, notably antibiotics, pain relievers, health supplements, and injectables. Large MNCs such as Pfizer, Schering Plough, Novartis, Eli Lilly, and Astra Zeneca are mostly licensed importers. Local distributors sell their products in the country, which are largely branded drugs (MIDA 2020, 4).

Regulation Process

In Malaysia, the pharmaceutical industry is regulated by the National Pharmaceutical Regulatory Agency (NPRA), an institution under Malaysia's Ministry of Health (MOH) (Pharmaceutical Association of Malaysia 2018, 6; MIDA 2020, 24). It “*was given the task of ensuring the quality, efficacy and safety of pharmaceuticals through the registration and licensing scheme*” (NPRA 2022). To register a product, companies must follow the guidelines outlined in the “Drug Registration Guidance Document”, where legal requirements and other related legislations are included (MIDA 2020, 25). Depending on the type of pharmaceutical, a full registration evaluation can take up to 116-245 working days (NPRA 2021).

Pricing and Reimbursement

In Malaysia, there is no price control mechanism for pharmaceuticals. In truth, it is up to market forces to create competition. However, the MOH employs a few pricing control measures in the public sector to guarantee that medicine costs are fair, reasonable, affordable, and steady. However, there are still difficulties that must be addressed. The main challenge in the public sector is the rising cost of pharmaceuticals. Similarly, in the private sector, the majority of private health care providers would not offer drugs at the suggested retail price (Hassali et al. 2015, 171). To address those challenges, recent announcements as of July 2022 have reported that the federal government is working on a drug price transparency mechanism, intended to make pharmaceutical companies divulge their drug development expenses, allowing the government to establish a “fair and acceptable price” for specific drugs (CodeBlue 2022).

Intellectual Property

According to the 2022 International IP Index, Malaysia increasingly recognizes IP as a valuable economic asset and actively supports its usage, reaching a score of 51.9%, ranking 27th (Pugatch and Torstensson 2022, 6). Previously, this index rating dropped when the country imposed compulsory licensing for Gilead Sciences' Hepatitis C therapy Sovaldi in 2017. Despite Gilead's

decision in August 2017 to voluntarily expand its Human Immunodeficiency Virus (HIV) and Hepatitis C generic licensing agreement to include Belarus, Malaysia, Thailand, and Ukraine, Malaysia's government gave the country's MOH the go-ahead to execute the compulsory license. This decision reflected the urgency of the country's escalating Hepatitis C prevalence and the necessity for increased patient access to inexpensive treatment. However, the decision was described as undermining Malaysia's IP environment (GlobalData 2022b, 24).

Ownership Equity

Since 2009, several sub-sectors in Malaysia were liberalized in terms of equity conditions. Since then, 100% foreign equity ownership is allowed for pharmaceutical companies entering Malaysia (PwC 2017a, 18).

Ease of Doing Business

As a result of governmental efforts that made it simpler to start a business, Malaysia improved its ranking in the World Bank's Ease of Doing Business 2020 Report to 12th from 15th in 2019 with an overall score of 81 out of 100. After Singapore, Hong Kong and South Korea, Malaysia is currently ranked as being the fourth-easiest location to do business in Asia, an improvement from an earlier ranking that put Malaysia in fifth place (World Bank 2021b). Figure 8 depicts the 10 categories that the ease of doing business index comprises as well as Malaysia's respective ranks. It should be noted that a low rank signifies a positive position.




Figure 8: "Ease of Doing Business" Categories for Malaysia in 2021, Source: Own illustration based on (World Bank 2021b)

Tax Liability

Table 3 depicts the current tax rates for corporate income, branch profit as well as the Value Added Tax (VAT). Several tax incentives are provided for foreign investors in various sectors, including R&D activities (MIDA 2022).

Category	Chargeable Income	Tax Rate
Corporate Income Tax Rate:		
Net Profit > 50mn MYR (\$11.35mn USD)		24%
Net Profit < 50mn MYR (\$11.35mn USD)	On the first 600,000 MYR	17%
Net Profit < 50mn MYR (\$11.35mn USD)	In excess of 600,000 MYR	24%
Branch Profit Tax Rate		24%
Value Added Tax (Sales)		10%
Value Added Tax (Service)		6%

Table 3: Tax Liabilities in Malaysia, Source: Own illustration based on (PwC 2022b; 2022c)

5.1.4 Qualitative Research Findings

In the following, the qualitative research findings on the pharmaceutical industry in Malaysia are outlined.

5.1.4.1 Past Development and Current Situation

Regarding the development of the pharmaceutical industry in Malaysia during the last decade, E9⁷ points out that the industry was steadily growing with a growth rate of 6-7% annually, despite the challenges of COVID-19. Especially in the general health area, like cardiology, endocrinology, oncology and rheumatology, the growth was visible according to E9.

Today, the market is worth around \$2bn USD (E8, E9, E10), accounting for 12.3% of the total healthcare spending for the last ten years according to E10. However, according to E9, the expenditure has to steadily grow in the future, mostly due to the aging population. It is pointed out that the government relies a lot on the pharmaceutical industry and thus finances 35% of the hospital expenditure by universal healthcare (E9, E10). By E10 it gets confirmed that the Malaysian government is the largest customer for all pharmaceutical products due to government hospitals being the largest channel for pharmaceutical product distribution. Thus, there is little pressure on pricing and mostly registered, well known patented drugs are used for

⁷ In all subsequent parts, the experts are abbreviated to E and a corresponding number. The complete list of experts can be found in Appendix 10.

the general population. The consumption is dominated by innovative and branded products, however, local manufacturers mostly produce generics. E10 points out that there are currently 74 generic manufacturers, however they only control 3% of the market.

5.1.4.2 Strengths and Challenges

The Malaysian pharmaceutical market is dominated by regulated products with the grey market playing an insignificant role. This is mostly based on the so-called “blue book”, pointed out by E8 and E10, listing 360 medicines to be distributed into the government hospitals. Those are mainly innovative, but also generic products in order to make a lot of generic companies find a customer in the government. According to E10, this is of high importance since one cannot find that many generic alternatives in the private sector. This leads to one of the main challenges that the Malaysian market is facing according to E10: Malaysia does not have a dispensing separation in the private sector. Unlike in mostly all other developing or developed nations, where the generic name instead of the brand name is prescribed, allowing the patient to have a choice to choose the cheaper generic, in Malaysia there is no separation. This leads to the rise in cost of private healthcare as well as a push towards branded products. Further challenges that are pointed out according to the experts are the limitation of the market in terms of size (E12) as well as the duration of registering new products (E8).

5.1.4.3 Market Entry Conditions

Regarding the **competitive landscape**, it is stated by E7 and E9 that the market is dominated by foreign pharmaceutical companies, amplified by E7 highlighting that out of the top ten companies there are only two domestic companies. Although there is domestic competition, more than 80% of the products are imported from MNCs like Sanofi, Novartis or GSK, mainly from the EU, US or UK. Among other things, this is due to key opinion leaders even in government being prone to EU firms according to E9. Further, E9 states that the Malaysian production capability is considered to be at an “infancy stage”, not being able to produce products as advanced or complex as products being able to be produced by German companies.

Although E9 highlights that a lot of products are imported from Germany, due to E7, the product availability and visibility of German companies is not as great as the one from other EU companies. E7 meets the assumption that they don't have an own entity set up but rather an agent or distributor in the market. However, E9 points out that consumers prefer German products over products from manufacturers elsewhere in EU and those EU products over Indian products. Besides the relation between local and foreign competition, especially E10 is highlighting the relation between innovator and generic products. Due to the patents, there is few competition between the two types of products. However, innovators are promoting their branding especially for orphan products already in the early stages to create a very strong allegiance between the dispenser and the innovator for later stages, when substitutes are available. According to E10, this is supported by the general assumption of doctors that generics are not as good as innovator products. To incentivize private clinics and pharmacies to dispense generics, they are significantly increasing their margins compared to branded products (E10).

Malaysia was the first country after Singapore among SEA to be accepted into the Pharmaceutical International Cooperation Scheme (PCIS) membership, meaning that the nation must adhere to a similar **regulatory landscape** than other member countries, mostly being developed nations (E7). This is consistent with a further statement by E7, pointing out that Malaysia is “Western focused” in terms of both regulatory and ethical regime. Since this is giving confidence to foreign investors to come in without having to worry about the protection of their brand, integrity, or IP, Malaysia is considered as a good base in terms of regulatory environment, as well if companies want to expand further within the region (E7). Regarding the setup of a company, one can differentiate between two modes: when only setting up a marketing or distribution office, the process is described as “straightforward” (E7, E10). However, it is pointed out that the market entry is not quick, since the product registration takes about 1.5 to two years (E7, E10). This period extends to four to five years before being able to

commercialize when companies want to set up a manufacturing entity, since there is more approval and qualification needed (E7). However, for both modes it is pointed out that the setup itself is not difficult, but the main challenge is to get the product approval, especially if the product has not been approved anywhere else (E7, E10). If the product is qualified and certified by the European Medical Association (EMA) or US Food and Drug Administration (FDA), it has already undergone the clinical trials and safety requirements in order to be approved by the NPRA (E7, E10). Although 100% foreign ownership is possible (E7, E9), E7 points out that it might be useful to partner up with a local company to cut short a big share of the registration period lengthwise. Further, E10 states that a separate set of rules might apply if companies want to supply to the government, which might be especially important for branded products.

Depending on the business model and mode of entry, German pharmaceutical companies entering the Malaysian market should approach different **local contacts**. According to E10, one can differentiate between three different types. As German innovator company holding a patent and wanting to serve manufacturing, especially the MOH (allowing to set up the business and give the manufacturing license according to the Good Manufacturing Practices (GMP) standard) as well as the NPRA (to register the formulation and product) are highly important authorities. This as well applies to the second type, a German company wanting to join with a domestic generic company to supply a combination. Next to engaging with the MOH and NPRA, the company must reach out to one of the 74 local generic manufacturers and especially engage with the customs authorities to approve the imports license. Lastly, if the German company wants to appoint a distributor, it will have to reach out to one of the 30 distribution companies but still must register the product with the NPRA. Optionally, the distributor can be given the right to register, easing some processes for the foreign company (E10). E7 and E9 confirm that having a local partner is advantageable in terms of shorter length of approval and set up as well as the acceptance of the product into the government facilities.

According to the credo “buy Malaysian first”, products viewed as locally produced have a higher chance of being purchased by the MOH (E7).

5.1.4.4 Opportunities and Risks for German SMEs

The Malaysian pharmaceutical market is considered an advanced market (E12) in terms of standards and regulations (E10) while being considered an untapped market in terms of knowledge base (E10). Thus, for German SMEs expanding to Malaysia, there are opportunities and risks that arise out of this status. Based on the strengths of German pharmaceutical companies, it might be an opportunity to bring in innovative formulations or unique generics, especially for local key chronic illnesses like cancer, diabetes, or obesity (E10). According to E10, the higher the national demand and the higher the product market fit, the more national players like business partners or further local contacts are willing to cooperate. E10 especially highlights the role of academic institutions, that are “hungry for collaboration” in terms of scientific research. Since the industry has a straightforward registration process and a distribution platform that is already robust, German SMEs could come into the market and “plug and play” to enable a quick market entry for new and innovative products (E10). It is highlighted by several experts that Malaysia, being “in a basket of Asian impact countries” (E10) offers an optimal base and springboard to populate into other SEA or Asia Pacific countries – main reasons being the safe and highly controlled market, ease of accessing key resources and low level of language barrier due to English being the most prominent language (E7, E9, E10). E9 points out that, due to the regulatory harmonization, products that are once approved in Malaysia are as well recognized throughout the ASEAN region. In conclusion, E10 summarizes: *“So you can be safe to say that if you meet those stringent requirements, you will have a market. But the question that you have to answer is whether that market is enough for that company?”* Emphasis is put on the limitations of the market in terms of size, where it is crucial to consider if the ratio of investment and return is sufficient if one only looks at the Malaysian market. Next to the market size, the market development got mentioned as critical

factor. When considering generics, the future development of dispensing separation might be a major challenge whereas for innovator products, the low level of knowledge might be critical (E7, E10) – however, it is mentioned that the market currently experiences a steep climb whereas maturity will only be reached within the next three to five years (E7). Further, in terms of market entry conditions, the length of the registration timeline, the stringent product approval guidelines as well as identifying optimal local partners are highlighted by several experts as challenges that might arise during the expansion process (E7, E10). Moreover, the high dependency on doctors and pharmacies in terms of prescription and dispensing, on government subsidiaries and on medical tourism are mentioned as potential risks by E9 and E10.

To conclude, Malaysia offers both an advanced and controlled pharmaceutical market as well as a vibrant business environment easing market entry for foreign investors. However, the market is limited in size and is facing challenges primarily regarding the future development of the dispensing separation and length of product registrations. Figure 9 summarizes the findings which result from the in-depth analysis. Furthermore, a Porter's Five Forces analysis for Malaysia can be found in Appendix 13.




Figure 9: SWOT Analysis for Malaysia, Source: Own illustration based on literature review and findings of expert interviews

6 Overarching Qualitative Research Findings regarding an Internationalization to MIT

In the following, overarching findings not specifically attributed to an expansion to one concrete country but to MIT obtained from the expert interviews are elaborated on.

6.1 German Expertise

Experts have differing views on whether Germany has a reputation for being an exceptionally reliable partner. E5 argues that Germany can benefit from its reputation of being well organized and “structured in the way to approach things” (E5). In contrast, E2 indicates that this positive image “diluted in the past few years rapidly” and that Germany “loses its great position as being a reliable, high-quality partner” (E2). Besides, E5 highlights that “people don’t care where a drug is from if it is from Germany or not... it’s more about the branded name and about the marketing advocacy“ and that the efficacy of the drug is important. A major risk for German pharmaceutical companies is risk aversion regarding investments in “future technologies” and in R&D for “novel technologies”. As E1 states, *“sometimes we are missing out on big opportunities [...]”*.

6.2 Market Entry Conditions

Regulatory environment

E2 and E5 point out that the markets in MIT are getting increasingly demanding in terms of trials and studies for pharmaceutical manufacturers. This involves conducting additional local clinical trials instead of just submitting past international clinical studies that were carried out in another country as well as providing profound stability data (E2).

Entry Mode/Local Contacts

Common entry modes for German SMEs are forming a joint venture with a local company (E1), licensing the medical products out to a local player (E6) as well as the distributor model (E3). According to E2, building a sustainable and long-term business network with local partners enables one to absorb expertise about the local markets and cultures (E2, E4, E6), benefit from their network connections, and delegate responsibilities regarding regulations, pricing, and

market access (E1). E2 recommends visiting international congresses to meet potential business partners from MIT. When selecting local business partners, several aspects should be considered. Firstly, checking the firms' compliance with local laws and alignment with German laws prevents regulatory issues in the future (E6). Moreover, the company focus is integral to ensuring alignment and compatibility. Some distribution firms emphasize ethics, some are specialized in OTC, some in B2B, and others in B2C (E2). E2 states that a criterion for exclusion could be when the distributor already works for a direct competitor.

Advice

It is of utmost importance to acquire a proper understanding of the markets in MIT (E1, E4), as German pharmaceutical SMEs cannot just implement their native strategy (E1). An evaluation of the respective culture and cultural differences is essential in choosing the right market (E2).

6.3 Opportunities and Risks for German SMEs

Numerous experts agree that entering MIT, so-called “*growth markets*” within a “*fantastic growth*” phase, offers a plethora of opportunities for future business growth due to the steep economic growth journey throughout the last years (E1, E2, E3, E4, E5, E14). According to E3 and E14, the most significant opportunity lies in the limited treatment and healthcare access. German companies that can afford investments in a long-term horizon will experience this growth potential over time (E1). E2 further points out that the opportunities are exceptionally high if German companies bring in a sophisticated, unique product or technology. Although the demand for innovative drugs is high (E2), German SMEs would have to make sure that the innovative drugs are accepted into the public sector and have a product market fit since any pharmaceutical with a premium pricing target for a rare patient type carries a high risk (E3). In terms of product quality, it might be challenging to consider and evaluate foreign quality standards in advance (E4), especially if there is no compliance with the standards to which EU pharmaceutical companies adhere. Not only can this damage the brand reputation but also the lives of patients (E6). According to E4, the markets in MIT are not yet full of European or

German companies. Besides that, several experts mention various dependencies that pose uncertainties for German SMEs expanding to SEA. On the one hand, geopolitical tensions with conflicts below the surface get mentioned (E2, E3). Moreover, E1 points out a dependency on general economic development, which influences the local ability to pay for innovative drugs and legal development, highlighting the role of IP challenges. E2 stresses that the governments in MIT show a “*strong tendency of protection of domestic markets and domestic players*”. It could be challenging to keep up with the local manufacturers if they are being pushed and privileged. In addition, E2 confirms that the local governments are focused on saving costs and, therefore, contain drug prices that might threaten the patented medicines market. Further overarching findings of the expert interviews can be found in Appendix 20.

7 Discussion

This paper aims to shed light on the business opportunities and risks for German pharmaceutical SMEs in Asia. The country selection process placed the focus on SEA and identified three countries (MIT) as potential expansion markets. After analyzing each country individually, this paper now compares the countries in question in the following dimensions: (1) Political, Economic, and Socio-Cultural Conditions, (2) Healthcare System, (3) Pharmaceutical Industry, including the Status Quo and Market Entry Conditions. On this basis, the ideal country for expansion into SEA for German SMEs is identified.

The first dimension refers to the political, economic, and socio-cultural conditions. Regarding the **political environment**, Malaysia stands out as the country with the lowest political risk, scoring 2 out of 7 points, compared to Thailand and Indonesia, with both scoring 3. The same accounts for the Corruption Perception Index, which ranks Malaysia as 62nd out of 180 countries, followed by Indonesia as 96th, and Thailand as 110th. Looking at the **economic situation**, Indonesia has the largest economy with a GDP of \$1.19tn USD, compared to Thailand with \$505.98bn USD and Malaysia with \$373bn USD. In contrast, Malaysia has the highest GDP per capita at \$11,371 USD, outperforming Thailand with \$7,233 USD and

Indonesia with \$4,292 USD (World Bank 2021e). This positions Malaysia as the most developed country with a high level of prosperity and economic strength. Furthermore, Indonesia is classified as a lower middle-income economy, while the others are classified as upper middle-income economies.

With regard to **socio-cultural conditions**, Hofstede's cultural dimensions are further analyzed (see Appendix 21). Evaluating potential cultural differences is crucial when choosing the right market (E1, E2, E12). Therefore, the cultural distance to Germany is compared to identify the market with the nearest distance. In this case, Thailand has the lowest cultural distance from Germany, with a score of 4.61, followed by Indonesia with 4.75 and Malaysia with 5.83⁸. Thus, Thailand provides the most favorable conditions from a cultural perspective for German SMEs to enter. However, it should be noted that all three countries have similar scores, tending to be further away from Germany. In summary, Malaysia stands out when considering political, economic, and socio-cultural conditions. Although the country has a greater cultural distance from Germany, its political system and economic development are highly advanced and offer the most favorable conditions for successful expansion.

Comparing the **healthcare system dimension**, Indonesia's healthcare spendings are the highest (see Table 9 below). However, per capita healthcare expenditure and expenditure as % of GDP are significantly lower than in the other countries. This demonstrates that the Indonesian healthcare system is lagging behind and still struggling in terms of financial burden and level of development. To compare, Malaysia already has an efficient healthcare system with excellent infrastructure and high-quality services, even leaving behind Thailand, which has a well-developed system as well. To conclude, although Indonesia represents the largest healthcare market, it is still in the early stages of development, while Thailand and Malaysia are already well developed. Here, Malaysia excels with the most advanced healthcare system.

⁸ The calculation can be found in the "Country Selection" Excel file.

2021	Malaysia	Thailand	Indonesia
Total health expend. (in mn USD)	\$15,350	\$18,706.98	\$32,900.77
Total health expend. as % of GDP	4.5	4.1	3.1
Per capita healthcare expend. (in USD)	\$486 (2019)	\$296 (2019)	\$120 (2019)
Public health expend. – Total (in mn USD)	\$8,039	\$13,984.19	\$16,134.52
Private health expend. – Total (in mn USD)	\$7,310	\$4,722.82	\$16,766.25
Private health expend. – Out of pocket (in mn USD)	\$5,316	\$1,625.47	\$11,235.239

Table 4: Comparison on Healthcare Expenditure Data for MIT, Source: Own illustration based on (GlobalData 2022a, 18), (GlobalData 2022c, 26), (GlobalData 2022b, 20–21) and (World Bank 2019c)

The third dimension discusses the **pharmaceutical industry**. Considering the **status quo** of the prevalent pharmaceutical industries among the three countries, Indonesia has by far the largest industry value with almost \$12bn USD in 2021, compared to \$6.4bn USD in Thailand and \$3.8bn USD in Malaysia. Although a high and increasing industry growth rate can be noted for all countries, Indonesia experiences an outstanding growth of middle- and upper-class population, thus, leading to new demand for pharmaceuticals, especially in the private sector.

The **competitive landscape** in Malaysia, Thailand, and Indonesia is shaped by local manufacturers producing generic drugs and MNCs manufacturing innovative, patented drugs. Malaysian consumers are likely to prefer German products over other foreign products, but the market is lacking the visibility and availability of those. Thailand is facing a continuous influx of cheap generics from India and other proximate countries, leading to rising competitive pressure among generics manufacturers. Indonesia is confronted with regulatory issues for patent enforcement, low R&D investments, and a lack of highly skilled scientists, which encourages MNCs rather to import their patented pharmaceuticals instead of producing them locally. However, Indonesia's great economic growth and push of JKN will likely lead to rising demand for patented drugs in the future. Therefore, the market in Malaysia is currently suitable for new entrants for patented pharmaceuticals, while Thailand offers more favorable entry and market conditions for patented drugs and Indonesia, at the current time, for generic drugs.

The **regulatory landscapes** in MIT show similar conditions. While setting up a business is especially straightforward in Malaysia, the registration process for new products might be lengthy and difficult for products that have not yet been registered and certified elsewhere (e.g.

EMA or US FDA). According to the ASEAN regulatory harmonization scheme, if a product is approved in one of the three countries, it is automatically approved in the others, facilitating potential regional expansion.

While there is no formal **price** control mechanism in the private sector in MIT, Thailand's maximum selling prices are set by the manufacturer and cannot be increased by hospitals. In the public sector, all countries have drugs listings allowing for regulations of both product selection and price regulation. In Thailand, the governmental impact on price regulation is additionally amplified by containment strategies curbing drug costs.

With regards to **IP protection**, the 2022 International IP Index classifies Indonesia lowest among SEA with a score of 30.42%, followed by Thailand (35.78%) and Malaysia (51.9%). In all countries, challenges regarding compulsory licensing require IP protection improvements to be made in the future, which is especially important for innovator products. For foreign companies, Indonesia poses further obstacles as imported drugs forego protection and can be produced by local companies.

All three countries allow 100% **ownership equity** for pharmaceutical companies. The **ease of doing business** ranks Malaysia as the 12th, Thailand as the 21st, and Indonesia as the 73rd out of 190 countries. Malaysia outperforms Thailand and Indonesia in 7 out of 10 categories and offers the most favorable conditions for doing business overall.




Figure 10: Comparison on "Ease of Doing Business" Ranks for MIT, Source: Own illustration based on (World Bank 2021b; 2021c; 2021a)

Malaysia, Thailand, and Indonesia have a similar range of **tax rates**. Malaysia has the highest standard CIT rate at 24%, while Thailand has the lowest standard CIT rate at 20%. However, all three countries offer tax incentives for SMEs.

In the view of all aspects analyzed, the **opportunities and risks** that result for the three countries can be discussed. In terms of market size, Malaysia is the most limited for German SMEs seeking growth potential, but Indonesia provides significant opportunities, particularly in terms of middle- and upper-class population growth. However, Thailand, with by far the highest per capita expenditure on pharmaceutical products and a population more than twice the size of Malaysia, offers significant growth opportunities as well. Local competition in all markets is usually prone to the development of generics, whereas MNCs bring in innovative and branded products. Because the government is one of MIT's largest customers in the pharmaceutical industry, it is eager to promote local businesses through listing activities or price control methods. Thus, it might be challenging for German generic manufacturers to compete with local companies since the markets are already saturated and local companies are favored. Furthermore, companies from China and India are entering the market, particularly in Thailand, and increase competitive pressure. In all countries, the market for innovative pharmaceuticals is not yet saturated, offering potential for foreign companies. In particular, innovative formulations for local key chronic illnesses (e.g. NCDs like diabetes) that experience increasing demand and thus, potentially offer an optimal product market fit might be a promising opportunity for German SMEs. Considering the government being one of the largest customers in all three markets and tending to favor local companies, as a foreign company, it is of utmost importance to bring in a medication that treats common illnesses to potentially be registered in the publicly available medications listing. However, in the public sector, competing on the low-price level is challenging due to budget constraints regarding healthcare spending, especially for innovative products in Thailand and Indonesia. In Indonesia

particularly, it might be challenging to bring in innovative products nowadays considering the large presence of low-priced pharmaceuticals. Since there are no price control mechanisms yet in Malaysia, this market potentially offers higher flexibility when setting prices. Considering the challenges arising in the public sector, the private sector functions as a significant opportunity for German innovator products. On the one hand, the population is looking into established brand names from Western countries, and, on the other hand, prices are higher on average compared to the public sector. Considering the rapid growth of Indonesia's private sector, new opportunities might arise for German SMEs in the long run. In Malaysia, the missing dispensing separation and the resulting dependency on doctors that are favoring local companies might be challenging when entering the market without a local partner. When analyzing and comparing the safety of MIT markets in terms of IP and ethical constraints, the Malaysian market appears as the most advanced and regulated one. Thailand and Indonesia face security and corruption challenges which poses potential obstacles for German SMEs. Similarly, in terms of the business environment, Malaysia encounters fewer challenges than Thailand and Indonesia. English as the prominent language and similarities in doing business provide favorable conditions for a market entry by German SMEs. However, entering partnerships with local companies could ease these challenges in doing business in Thailand and Indonesia. Especially in Indonesia, there are considerable challenges to establish a logistical and commercial infrastructure due to the fragmented geographical situation. Thus, it is of utmost importance for German SMEs to cooperate with a local distributor experienced in the market. Further opportunities of partnerships arise in Malaysia where German SMEs could collaborate with academic partners for scientific research which could potentially be favoring the relationship to the government to a large extent. To conclude, different opportunities and risks are prevalent among the MIT markets.

In summary, Figure 18 provides an assessment of each dimension and its subcategories, categorized as low (red), medium (yellow), and high (green).

DESCRIPTION	MALAYSIA	THAILAND	INDONESIA
Political, Economic and Socio-Cultural Conditions			
Healthcare System			
Pharmaceutical Industry (Overall Score)			
Status Quo			
Market Entry Conditions			
<i>Competitive Landscape</i>			
<i>Regulation Process</i>			
<i>Pricing & Reimbursement</i>			
<i>Intellectual Property</i>			
<i>Ownership Equity</i>			
<i>Ease of Doing Business</i>			
<i>Tax Liability</i>			

Figure 11: Assessment of Dimensions for MIT, Source: Own illustration based on in-depth analyses and discussion

To conclude, Malaysia is categorized as “high” in every dimension and hence, offers the highest potential for internationalization efforts. It is followed by Thailand which is classified as “high” in two out of five dimensions, and Indonesia, with no dimension categorized as “high”. The next chapter addresses related strategic actions regarding this outcome.

8 Strategic Guidelines and Recommendations

Based on the discussion, the following chapter derives strategic recommendations with the help of the WH questions “Who?”, “Where?”, “When?”, “Why?” and “How?”. The market entry to Malaysia is illustrated in the form of a strategic 5-phase action plan. Subsequently, an expansion roadmap reflects the medium- and long-term horizon.

Who?

German pharmaceutical SMEs can bring the necessary expertise in terms of talent and scientific competence for manufacturing innovative, patented medicines for the MIT markets. Although risk aversion towards new technologies or investments into R&D for producing innovative pharmaceuticals might be common among German companies, the ones who seize the chance can grasp the arising business opportunities. Therefore, German SMEs are recommended to

focus on the innovative pharmaceutical market rather than on the generic market. It may be mentioned in this context that a stable presence in the home country is a vital prerequisite for expansion success to another continent.

Where and When?

Based on the output of the discussion, a long-term perspective is taken on. The MIT markets show expansion potential for German pharmaceutical SMEs and as the country selection was performed within the frame of achieving potential ease of expansion within a region, all three markets are considered for market entry. In this regard, the regulatory harmonization in terms of the ASEAN agreement is a convincing argument. However, each country is suitable at a different point in time due to the individual development levels. This results in the following chronological order of expansion: (1) Malaysia, (2) Thailand, (3) Indonesia.

Why?

At first, Malaysia provides the most favorable market conditions given the defined strategic focus of German pharmaceutical SMEs. The company establishment in Malaysia is facilitated by the advanced market in the examined aspects and by the consumer openness for patented drugs from Germany. Considering international price referencing, it is strategically reasonable to commence the expansion process in Malaysia, where there is no price control mechanism and prices can be set the highest among the MIT countries. Therefore, although the country and population size are smaller than in Thailand and Indonesia, it can be advantageous to start the SEA expansion with a manageable target consumer market and leverage on the growth phase that Malaysia is experiencing.

Subsequently, it is reasonable to enter Thailand as the second market in the region due to the larger market size and its growth trajectory. The market for innovative drugs experiences less competitive pressure than the generics market and is not yet fully saturated and fragmented. Moreover, the high per capita expenditure on pharmaceutical products is attractive with regard

to selling innovative drugs. The acquired operating experience from Malaysia can be utilized to prepare the market entry to Thailand with a more practical angle of view and learn from first-hand experiences within the SEA region.

Indonesia is attractive to enter as the third country as it is amidst its growth journey. Currently, the Indonesian market is suboptimal for the intended purpose of German pharmaceutical SMEs due to the favorable conditions for generics and the high protection for local manufacturing. Nevertheless, it is expected to develop into a market with a high demand for patented drugs in the future due to the vast consumer market and the rising spending power. Therefore, Indonesia offers ideal preconditions for German pharmaceutical SMEs only in several years, but when the time arises, companies can reap the benefits that the country provides. In the meantime, the German SME will have adopted a holistic view of how to do business in the SEA region and will be adequately prepared to enter a market of this size.

How?

In the following, concrete steps for the expansion to Malaysia are outlined in the form of a 5-phase action plan (see Table 10).

The first phase is the **Assessment of the Status Quo**, as German SMEs have to evaluate their presence in the market of origin to diagnose the current situation. They should perform an internal analysis, including the assessment of firm-specific advantages and country-specific advantages and the motives for internalization. For German SMEs, this step is crucial since they need to assess their global readiness and evaluate whether they are prepared to expand internationally. Further, the industry has to be analyzed using Porter's Five Forces model, for instance. Last, the growth potential within the current market environment should be estimated.

Phase two reflects the **Internationalization Strategy** in the present period of time. It includes the decision on the expansion country, the corresponding entry strategy with the selected entry mode as well as a thorough understanding of how to sustainably succeed. Here,

the goal setting for the expansion process including specific, measurable, achievable, relevant, and time-bound objectives plays a key role. Beyond that, phase two implies the communication of the brand's value to the stakeholders. It is noteworthy that, although MIT are located in the SEA region, the countries differ in terms of culture and market pain points. Therefore, the product-market fit should be elaborated on a country level instead of a regional level. Nevertheless, the rising NCDs are creating a target-rich setting for the corresponding therapeutic areas in all three countries and are worth considering as a focal field.

When **Preparing the Market Entry** into Malaysia as the first country among MIT in phase three, the conditions and length of registration processes play a significant role. Although setting up a business is quick and straightforward in Malaysia, registering a pharmaceutical product might be lengthy and requires planning in advance. Especially market access regarding clinical trials needs to be examined beforehand since ensuring compliance with local regulations is inevitable. While authorities like the Malaysian Investment Development Authority or the Malaysian-German Chamber of Commerce and Industry offer support by providing general market information and services, the Malaysian MOH and NPRA are the most important contacts to receive industry-specific assistance. Moreover, it is recommended to build local partnerships with distributors, academic institutions, and consultancies to leverage on the local knowledge and network. It can be strategically beneficial to consider DKSH and Zuellig Pharma as distributors due to their presence in all three markets. This might make consecutive market entries easier, more efficient and can even accelerate the whole expansion process. In order to prevent regulatory and compatibility issues in the future, key aspects like the firms' compliance with local and German laws as well as the company direction, namely OTC, B2B, B2C, or ethical focus. Reaching out to the Faculty of Pharmacy of the University Malaya or consultancies specialized in market access to Malaysia like "3E Accounting" further

offers the potential to strengthen local market knowledge. Local contacts can be acquired online or via pharmaceutical fairs like the annual “Convention on Pharmaceutical Ingredients”.

In the fourth phase, the actual **Market Entry** phase, human resource efforts and relationship building with stakeholders play a key role. German pharmaceutical SMEs are advised to be aware of possible cultural differences. To support German employees in practicing cultural intelligence, organizing cross-cultural trainings is crucial. Further, efforts to hire local talent can be carried out at this stage. Besides building employee relationships, client relationships should be established. Apart from reaching out to private clinics and pharmacies, the government as the largest customer has a significant impact on the market dynamics.

Phase five involves the medium- and long-term perspective for **Further Market Expansion**. Here, monitoring the business performance and assessment of goal completion is essential. This allows to adapt the strategy, if necessary, and be able to adequately prepare the following market entries to Thailand and Indonesia.

Table 10 shows the 5-phase action plan for Malaysia and highlights the required duties and specific actions within the time horizons.

Phase	Phase 1: Assessment of the Status Quo	Phase 2: Internationalization Strategy	Phase 3: Entry Preparation Malaysia	Phase 4: Market Entry Malaysia	Phase 5: Further Market Expansion
Time Horizon	Present Time	Present Time	Short-Term	Short-Term	Medium- & Long-Term
Necessary Steps	- Internal Analysis - Firm-Specific Advantages & Country Specific Advantages - Motives for Internationalization - Industry Analysis - Assess Growth Potential within Market of Origin	- Where to Play? - How to Enter? - Analysis of Entry Strategy and Selection of Entry Mode) - How to Sustainably Succeed? - Goal Setting for Expansion - Communication of Brand's Value to Stakeholders (Payers) - Identify Product-Market Fit	- Registration Processes - Business Set Up - Product/Formulation - Clinical Trials - Research Local Partners and Establish Contracts - Authorities - Distribution - Academic Institutions	- Cross-Cultural Trainings - Hiring Process of Local Talent - Build Customer Relationships e.g Government, Public & Private Hospitals, Pharmacies etc.	- Monitor and Adapt Strategy within the Internationalization Process in Malaysia - Assess Goal Completion - Prepare Further Market Entries

Table 5: 5-Phase Action Plan, Source: Own illustration

Beyond that, the expansion roadmap below (Figure 19) illustrates the medium-term perspective for Thailand and the long-term perspective for Indonesia. Here, it should be noted that the 5-phase action plan set up for Malaysia is applicable to Thailand and Indonesia as well.



Figure 12: Expansion Roadmap for Medium- and Long-Term Perspective, Source: Own illustration

9 Conclusion

This paper aimed to thoroughly investigate potential markets appropriate for German pharmaceutical SMEs to consider for internationalization to Asia. After an overview of the German pharmaceutical industry and expertise was provided, a country selection process was performed, with Malaysia, Thailand, and Indonesia being chosen as potential markets to enter. Thus, an in-depth market examination was conducted for these three markets, analyzing political, economic, and socio-cultural factors, the healthcare industry, and various aspects of the pharmaceutical industry. After considering all factors by consolidating and comparing the opportunities and risks for German SMEs in each market, it was discovered that all three countries offer potential when considering a long-term perspective. From a short-term view, Malaysia was identified as an ideal starting country due to its favorable market conditions, functioning as a hub for further expansion for entering Thailand and Indonesia in the medium- and long run. Taking all countries into consideration enables German SMEs to utilize the different opportunities in each country and to leverage regional synergy effects like regulatory harmonization or the ability to cooperate with similar partners in all markets. Finally, a roadmap serving as a guideline for the long-term internationalization process was developed, narrowing down the necessary steps for expansion.

To conclude, expanding into MIT markets represents a significant opportunity for German pharmaceutical SMEs to grow and establish a strong market position in SEA.

10 Limitations and Future Research

Within the scope of this paper, there are several limitations as well as various aspects that are of particular interest for future research. One prevalent limitation of this paper is the incomplete survey examination. No further analysis was performed as the degree of representativeness of the sample, due to the lack of respondents, does not allow for drawing plausible conclusions. Future research could extend the current analysis by recreating and redistributing the created questionnaire to examine the consumer attitudes towards local vs. foreign pharmaceutical companies in MIT. Conducting the survey on a personal level on-site is more likely to receive a sufficient response rate⁹. In addition, due to resource constraints, only 14 interviews (15 participants) have been conducted as part of this university paper, resulting in a small sample size. This may affect the representativeness and quality of the resulting findings. Moreover, other markets within the SEA region could be analyzed and evaluated for a future market entry concerning the innovative focus of German pharmaceutical SMEs. Special attention can be paid to the Velocity 12 markets, namely India, China, Pakistan, Bangladesh, Philippines, Vietnam, and Myanmar, due to their fast-growing economies and dynamic environment. Furthermore, other stages of the supply chain of the pharmaceutical industry besides manufacturing could be considered for future research. Lastly, a thorough analysis of possible entry modes for internationalization would contribute to an improved expansion strategy.

Bearing the aforementioned supplementary study areas in mind, one should consider the subject's complexity due to the various angles of the pharmaceutical industry and the number of distinctive Asian markets.

⁹ E15 states that survey response rates are generally low when not performed face-to-face in MIT.

11 References

- Albrecht, Julia, and Gregor Kemper. 2021. "The Pharmaceutical Industry in Germany." Germany Trade & Invest.
- APO. 2013. "Malaysia Health System Review." *Health Systems in Transition* 3 (1): 1–91.
- Asian Development Bank. 2017. "Strong Asian Intraregional Trade and Investment Improve Economic Resilience." 2017. <https://www.adb.org/news/strong-asian-intraregional-trade-and-investment-improve-economic-resilience>.
- . 2022a. "Developing Asia Economies Set to Grow 5.2% This Year Amid Global Uncertainty." Asian Development Bank. 2022. <https://www.adb.org/news/developing-asia-economies-set-grow-5-2-year-amid-global-uncertainty>.
- . 2022b. "Southeast Asia Rising from the Pandemic." 0 ed. Manila, Philippines: Asian Development Bank. <https://doi.org/10.22617/TCS220093-2>.
- BMWK. 2019. "The German Mittelstand as a Model for Success." Federal Ministry for Economic Affairs and Climate Action. 2019. <https://www.bmwk.de/Redaktion/EN/Dossier/sme-policy.html>.
- . 2022a. "Europäische Handelspolitik." BMWK. 2022. <https://www.bmwk.de/Redaktion/DE/Dossier/handelspolitik.html>.
- . 2022b. "Europäische Mittelstandspolitik." BMWK. <https://www.bmwk.de/Redaktion/DE/Textsammlungen/Mittelstand/europaeische-mittelstandspolitik.html>.
- BPI. 2021. "Pharma-Daten 2021." Bundesverband der Pharmazeutischen Industrie e.V.
- Carlson, Brian G., Julian Kamasa, Linda Maduz, Niklas Masuhr, and Lisa Watanabe. 2021. *Strategic Trends 2021: Key Developments in Global Affairs*. Edited by Oliver Thränert. Zürich: Center for Security Studies (CSS).
- CEDAR. 2018. "Malaysia Pharmaceutical Market."
- CodeBlue. 2022. "MOH Demands Drug Pricing Transparency, Price Controls 'Last Resort.'" 2022. <https://codeblue.galencentre.org/2022/07/27/moh-demands-drug-pricing-transparency-price-controls-last-resort/>.
- Credendo. 2022. "Country Risk and Insights." 2022. <https://credendo.com/en/country-risk>.
- Deloitte. 2017. "Deloitte Report: Asia Will Be Home to 60% of World's over 65s by 2030, Creating Growth Opportunities for Business." Deloitte. 2017. <https://www2.deloitte.com/bd/en/pages/about-deloitte/articles/deloitte-report-creating-growth-opportunities-for-business.html>.
- Dickov, Veselin, Dragan Mitrovic, and Boris Kuzman. 2011. "Analyzing Pharmaceutical Industry." *National Journal of Physiology, Pharmacy and Pharmacology* 1: 1–8.
- EFPIA. 2022. "The Pharmaceutical Industry in Figures." European Federation of Pharmaceutical Industries and Associations. <https://www.efpia.eu/media/637143/the-pharmaceutical-industry-in-figures-2022.pdf>.
- European Commission. 2020. "User Guide to the SME Definition." https://single-market-economy.ec.europa.eu/smes/sme-definition_en.
- GlobalData. 2022a. "Country Report - Indonesia."
- . 2022b. "Country Report - Malaysia."
- . 2022c. "Country Report - Thailand."
- Greenbaum, Karen. 2018. "Executive Talent." *AESC*, Executive Talent, 13.
- Hassali, Mohamed Azmi, Ching Siang Tan, Zhi Yen Wong, Fahad Saleem, and Alian A. Alrasheedy. 2015. "Pharmaceutical Pricing in Malaysia." In *Pharmaceutical Prices in the 21st Century*, edited by Zaheer-Ud-Din Babar, 171–88. Cham: Springer International Publishing. https://doi.org/10.1007/978-3-319-12169-7_10.

- Herr, Hansjörg, and Zeynep Mualla Nettekoven. 2018. "The Role of Small and Medium-Sized Enterprises in Development: What Can Be Learned from the German Experience?," 63.
- Hester, R. E., and Roy M. Harrison, eds. 2016. *Pharmaceuticals in the Environment*. Issues in Environmental Science and Technology 41. Cambridge: Royal Society of Chemistry.
- Hofstede Insights. 2022. "Country Comparison." 2022. <https://www.hofstede-insights.com/country-comparison/germany,indonesia,malaysia,thailand/>.
- Holloway, Immy. 2005a. *Qualitative Research in Health Care*. UK: McGraw-Hill Education. <https://www.lsms.ac/public/uploads/088yDTJdPYq2CdggLCOXp0GpOxDbRBTRJX7hr1xArq5zatQJIC1575401043loPcbB14GXaS61brpLxhjd61QG6J8x1fwdWZ54o7vL6f01eHSQ.pdf>.
- . 2005b. *Qualitative Research in Health Care*. UK: McGraw-Hill Education. <https://www.lsms.ac/public/uploads/088yDTJdPYq2CdggLCOXp0GpOxDbRBTRJX7hr1xArq5zatQJIC1575401043loPcbB14GXaS61brpLxhjd61QG6J8x1fwdWZ54o7vL6f01eHSQ.pdf>.
- Institute for Public Health. 2017. "Malaysia Burden of Disease and Injury Study 2009-2014." <https://iku.moh.gov.my/images/IKU/Document/REPORT/BOD/BOD2009-2014.pdf>.
- IQVIA. 2022. "IQVIA Marktbericht Classic - Entwicklung Des Deutschen Pharmamarktes Im Kalenderjahr 2021."
- Kawai, Masahiro, and Ganeshan Wignaraja. 2014. "Trade Policy and Growth in Asia." Asian Development Bank Institute.
- KPMG. 2022. "Economic Key Facts Germany." KPMG. 2022. <https://home.kpmg/de/en/home/insights/overview/economic-key-facts-germany.html>.
- Liu, Bruce. 2022. "Asia's Rise in The Global Pharma Industry." *Pharmexec* 42 (7): 10.
- MIDA. 2020. "Guide on Pharmaceutical Industry in Malaysia."
- . 2022. "Incentives." 2022. <https://www.mida.gov.my/setting-up-content/incentives/>.
- Mikulic, Matej. 2021. "Revenues of Top 10 National Pharmaceutical Markets Worldwide in 2020." 2021. <https://www.statista.com/statistics/266469/revenues-of-the-top-10-global-pharmaceutical-markets/>.
- NPRA. 2021. "FAQ : Product Registration." 2021. <https://www.npra.gov.my/index.php/en/component/content/article/37-english/faq/623-product-registration.html?Itemid=1391>.
- . 2022. "Regulation Basics." 2022. <https://www.npra.gov.my/index.php/en/regulation-basic.html>.
- Nuruzzaman, Syed, and Yusuke Tateno. 2021. "COVID-19 Pandemic and the Asia-Pacific LDCs: Impacts, Challenges, Gaps and Way Forward." United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP).
- Ochieng, Pamela Atieno. 2009. "AN ANALYSIS OF THE STRENGTHS AND LIMITATION OF QUALITATIVE AND QUANTITATIVE RESEARCH PARADIGMS" 13.
- OECD and EU IP Office. 2020. *Trade in Counterfeit Pharmaceutical Products*. Illicit Trade. OECD. <https://doi.org/10.1787/a7c7e054-en>.
- OECD and WHO. 2020. *Health at a Glance: Asia/Pacific 2020: Measuring Progress Towards Universal Health Coverage*. Chapter 6. Health at a Glance: Asia/Pacific. OECD. <https://doi.org/10.1787/26b007cd-en>.
- Ogilvy. 2016. "The Velocity 12 Markters. Reshaping the World View of Middle-Class Growth."
- Pharma Boardroom. 2021. "Top 10 Pharma Companies in Indonesia." 2021. <https://pharmaboardroom.com/facts/top-10-pharma-companies-in-indonesia/>.

- Pharmaceutical Association of Malaysia. 2018. "Industry Fact Book. Advancing the Health of a Forward Moving Nation."
- Pugatch, Meir, and David Torstensson. 2022. "2022 International IP Index: Compete for Tomorrow." Tenth Edition. U.S. Chamber of Commerce.
- PwC. 2017a. "Doing Business in Malaysia 2017."
- . 2017b. "Explore Healthcare Opportunities in Belt and Road Countries – Thailand."
- . 2020. "Pharma 2020: Supplying the Future. Which Path Will You Take?" <https://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020/assets/pharma-2020-supplying-the-future.pdf>.
- . 2022a. "Doing Business in Malaysia 2022."
- . 2022b. "Malaysia: Corporate - Taxes on Corporate Income." 2022. <https://taxsummaries.pwc.com/malaysia/corporate/taxes-on-corporate-income>.
- . 2022c. "Standard VAT Rates for WWTS Territories." 2022. <https://taxsummaries.pwc.com/quick-charts/value-added-tax-vat-rates>.
- Roser, Max, Hannah Ritchie, and Fiona Spooner. 2021. "Burden of Disease." Our World in Data. 2021. <https://ourworldindata.org/burden-of-disease>.
- Rudnicka. 2022. "Umsätze Der Wichtigsten Industriebranchen in Deutschland in Den Jahren von 2019 Bis 2021." 2022. <https://de.statista.com/statistik/daten/studie/241480/umfrage/umsaetze-der-wichtigsten-industriebranchen-in-deutschland/>.
- SESRIC. 2009. "Pharmaceutical Industry. Production, Consumption and Trade in OIC Member Countries." <https://sesricdiag.blob.core.windows.net/sesric-site-blob/files/article/433.pdf>.
- Simon, Hermann. 2016. "The German Mittelstand in Globalia." German-Asia-Pacific Business Association. <https://www.oav.de/iap-32016/artikel-210.html>.
- Song, Wanyuan. 2022. "What Is China's Zero Covid Policy and What Are Its Rules?" BBC. 2022. <https://www.bbc.com/news/59882774>.
- Statista. 2020. "The Rise of the Asian Middle Class." 2020. <https://www.statista.com/chart/8402/asian-middle-class-on-the-rise/>.
- . 2022a. "Global Pharmaceutical Industry - Statistics & Facts." 2022. https://www.statista.com/topics/1764/global-pharmaceutical-industry/#topicHeader__wrapper.
- . 2022b. "Per Capita Expenditure on Pharmaceuticals in Southeast Asia in 2020, by Selected Country." 2022. <https://www.statista.com/statistics/1291687/sea-pharma-spending-per-capita-by-country/>.
- . 2022c. "Total Global Spending on Pharmaceutical Research and Development from 2014 to 2028 (in Billion U.S. Dollars)." 2022. <https://www.statista.com/statistics/309466/global-r-and-d-expenditure-for-pharmaceuticals/#:~:text=In%202021%2C%20research%20and%20development,238%20billion%20U.S.%20dollars%20globally>.
- Stifterverband. 2021. "Zahlenwerk 2021." Stifterverband.
- Switzerland Global Enterprise. 2021. "MARKET REPORT: BUSINESS OPPORTUNITIES IN DIGITAL HEALTH IN MALAYSIA."
- Taylor, David. 2015. "The Pharmaceutical Industry and the Future of Drug Development." In *Issues in Environmental Science and Technology*, edited by R E Hester and R M Harrison, 1–33. Cambridge: Royal Society of Chemistry. <https://doi.org/10.1039/9781782622345-00001>.
- The Economist. 2018. "Making The Most of Opportunity: Pharmaceutical Strategy in Asia." The Economist Intelligence Unit Ltd.

- Tonby, Oliver, Jonathan Woetzel, Wonsik Choi, Jeongmin Seong, and Patti Wang. 2019. "Asia's Future Is Now." McKinsey.
- Transparency International. 2021. "Corruption Perceptions Index: Malaysia." 2021. <https://www.transparency.org/en/countries/malaysia>.
- Tunpaiboon, Narin. 2019. "Thailand Industry Outlook 2019-2021: Pharmaceuticals." Krungsri Research.
- UNESCAP. 2015. "Global Value Chains and Interconnectedness of Asia-Pacific Economies." In *Asia-Pacific Trade and Investment Report 2015*, 103. <https://www.unescap.org/sites/default/files/Chapter%207%20-%20GVCs%20in%20the%20Asia-Pacific.pdf>.
- . 2017. "Ageing in Asia and the Pacific: Overview." United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP).
- US FDA. 2017. "Prescription Drugs and Over-the-Counter (OTC) Drugs: Questions and Answers." 2017. <https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/prescription-drugs-and-over-counter-otc-drugs-questions-and-answers>.
- Vfa. 2022. "Weltweit an Der Spitze: Arzneimittel 'Made in Germany.'" 2022. <https://www.vfa.de/de/wirtschaft-politik/pharma-produktion-in-deutschland>.
- WHO. 2018. *How Pharmaceutical Systems Are Organized in Asia and the Pacific*. Manila: World Health Organization Regional Office for the Western Pacific.
- . 2020. "Noncommunicable Diseases." 2020. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>.
- Witt, Michael. 2021. "Malaysia: A Concise Profile, 2021." INSEAD.
- World Bank. 2019a. "Current Health Expenditure (% of GDP)." 2019. <https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS>.
- . 2019b. "Current Health Expenditure (% of GDP) - Malaysia." 2019. <https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=MY>.
- . 2019c. "Current Health Expenditure per Capita (Current US\$)." 2019. <https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD>.
- . 2019d. "Current Health Expenditure per Capita (Current US\$) - Malaysia." 2019. <https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD?locations=MY>.
- . 2019e. "Domestic General Government Health Expenditure (% of GDP)." 2019. <https://data.worldbank.org/indicator/SH.XPD.GHED.GD.ZS>.
- . 2019f. "Ease of Doing Business Score (0 = Lowest Performance to 100 = Best Performance)." 2019. <https://data.worldbank.org/indicator/IC.BUS.DFRN.XQ>.
- . 2020a. "Life Expectancy at Birth, Female (Years) - Malaysia." 2020. <https://data.worldbank.org/indicator/SP.DYN.LE00.FE.IN?locations=MY>.
- . 2020b. "Life Expectancy at Birth, Male (Years) - Malaysia." 2020. <https://data.worldbank.org/indicator/SP.DYN.LE00.MA.IN?locations=MY>.
- . 2021a. "Ease of Doing Business in Indonesia." 2021. https://archive.doingbusiness.org/en/data/exploreconomies/indonesia#DB_sb.
- . 2021b. "Ease of Doing Business in Malaysia." 2021. <https://archive.doingbusiness.org/en/data/exploreconomies/malaysia>.
- . 2021c. "Ease of Doing Business in Thailand." 2021. <https://archive.doingbusiness.org/en/data/exploreconomies/thailand>.
- . 2021d. "Exports of Goods and Services (Current US\$) - Germany." 2021. <https://data.worldbank.org/indicator/NE.EXP.GNFS.CD?locations=DE>.
- . 2021e. "GDP per Capita (Current US\$)." 2021. <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD>.
- . 2021f. "GDP per Capita Growth (Annual %)." 2021. <https://data.worldbank.org/indicator/NY.GDP.PCAP.KD.ZG>.

- . 2021g. “Imports of Goods and Services (Current US\$) - Germany.” 2021.
<https://data.worldbank.org/indicator/NE.IMP.GNFS.CD?locations=DE>.
- . 2021h. “Population, Total.” 2021.
<https://data.worldbank.org/indicator/SP.POP.TOTL>.
- . 2021i. “Population, Total - Bahrain.” 2021.
<https://data.worldbank.org/indicator/SP.POP.TOTL?locations=BH>.
- . 2021j. “Population, Total - Brunei Darussalam.” 2021.
<https://data.worldbank.org/indicator/SP.POP.TOTL?locations=BN>.
- . 2021k. “Population, Total - Germany.” 2021.
<https://data.worldbank.org/indicator/SP.POP.TOTL?locations=DE>.
- . 2021l. “Population, Total - Kazakhstan.” 2021.
<https://data.worldbank.org/indicator/SP.POP.TOTL?locations=KZ>.
- . 2021m. “Population, Total - Qatar.” 2021.
<https://data.worldbank.org/indicator/SP.POP.TOTL?locations=QA>.
- . 2022a. “GDP (Current US\$) - Malaysia.” 2022.
<https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?locations=MY>.
- . 2022b. “Population Growth (Annual %).” 2022.
<https://data.worldbank.org/indicator/SP.POP.GROW>.
- . 2022c. “Urban Population Growth (Annual %).” 2022.
<https://data.worldbank.org/indicator/SP.URB.GROW>.
- . 2022d. “World Bank Country and Lending Groups.” 2022.
<https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>.
- World Economics. 2022. “The Future Is Asian.” 2022.
<https://www.worldeconomics.com/Thoughts/The-future-is-asian.aspx>.
- ZEW. 2021. “Innovationen ZEW Branchenreport - Ergebnisse Der Deutschen Innovationserhebung 2021.” Leibniz-Zentrum für Europäische Wirtschaftsforschung.

12 Appendices

Appendix 1: List of Figures and List of Tables

List of Figures

Figure 1: German Pharmaceutical Industry Overview, Source: Own illustration based on (IQVIA 2022b, 7) ¹ , (BPI 2021, 6–7) ² , (ZEW 2021) ³	7
Figure 2: Free Trade Agreements in Asia, Source: Own illustration based on (Carlson et al. 2021, 110).....	10
Figure 3: Country Selection Dimensions and Variables, Source: Own illustration based on Country Selection Excel file	13
Figure 4: Country Ranking – Top 10 Countries.....	15
Figure 5: Country Clusters based on the Dendrogram, Source: Own illustration based on the “Output Country Clustering” SPSS file, can be found in the Country Selection Excel file	15
Figure 6: Country Selection Funnel, Source: Own illustration based on filters used for country selection.....	17
Figure 7: Health Expenditure in Malaysia, Sources: Own illustration based on (World Bank 2019h; 2019d)	21
Figure 8: “Ease of Doing Business” Categories for Malaysia in 2021, Source: Own illustration based on (World Bank 2021c).....	26
Figure 9: SWOT Analysis for Malaysia, Source: Own illustration based on literature review and findings of expert interviews	32
Figure 10: Health Expenditure in Thailand“ Source: Own illustration based on (World Bank 2019i; 2019e).....	35
Figure 11: "Ease of Doing Business" Categories for Thailand in 2021, Source: Own illustration based on (World Bank 2021d)	41
Figure 12: SWOT Analysis for Thailand, Source: Own illustration based on literature review and findings of expert interviews	46
Figure 13: Economic Key Facts Indonesia, Source: Own illustration	47
Figure 14: Health Expenditure in Indonesia, Source: Own illustration based on (World Bank 2019g) and (World Bank 2019c).....	48
Figure 15: "Ease of Doing Business" Categories for Indonesia in 2021, Source: Own illustration based on (World Bank 2021b)	55
Figure 16: SWOT Analysis for Indonesia, Source: Own illustration based on literature review and findings of expert interviews	60
Figure 17: Comparison on "Ease of Doing Business" Ranks for MIT, Source: Own illustration based on (World Bank 2021c; 2021d; 2021b)	38
Figure 18: Assessment of Dimensions for MIT, Source: Own illustration based on in-depth analyses and discussion	41
Figure 19: Expansion Roadmap for Medium- and Long-Term Perspective, Source: Own illustration.....	46


List of Tables

Table 1: Economic Growth in Asia, Source: Own illustration based on (Asian Development Bank 2022a)	9
Table 2: Selected Dimension and Variable Description and Reasoning, Sources in chronological order: (World Bank 2022e; 2022h; 2021l; 2019m; 2019f; 2019b; 2019j; Roser, Ritchie, and Spooner 2021)	14
Table 3: Tax Liabilities in Malaysia, Source: Own illustration based on (PwC 2022b; 2022c)	27
Table 4: Public Healthcare Insurance Schemes in Thailand, Sources: Own illustration based on (Dreyfuss 2018, 42–47; McManus 2012, 49; Switzerland Global Enterprise 2021b, 10)..	36
Table 5: Registration Fees for Pharmaceuticals Licenses in Thailand, Source: Own illustration based on (Adcock, Homhuan, and Chaithiraphant 2019, 9)	39
Table 6: Tax Liabilities in Thailand, Source: Own illustration based on (PwC 2022f; 2022d; 2022e).....	41
Table 7: Foreign Ownership Comparison in Indonesia, Source: Own illustration based on (Herbert Smith Freehills 2021)	54
Table 8: Tax Liabilities in Indonesia, Source: Own illustration based on (Deloitte 2021, 108–10).....	55
Table 9: Comparison on Healthcare Expenditure Data for MIT, Source: Own illustration based on (GlobalData 2022a, 18), (GlobalData 2022c, 26), (GlobalData 2022b, 20–21) and (World Bank 2019f)	37
Table 10: 5-Phase Action Plan, Source: Own illustration.....	45

Appendix 2: List of Abbreviations


APEC = Asian-Pacific Economic Cooperation
ASEAN = Association of Southeast Asian Nations
B2B = Business-to-Business
BOI = Board of Investment
CIT = Corporate Income Tax
CMSME = Cottage Small and Medium Sized Enterprises
CSMBS = Civil Servant Medical Benefit Scheme
EMA = European Medical Association
EU = European Union
FDA = Food and Drug Administration
FORNAS = National Formulary
GDP = Gross Domestic Product
GNI = Gross National Income
GPO = Government Pharmaceutical Organization
HIV = Human Immunodeficiency Virus
IDR = Indonesian Rupiah
IP = Intellectual Property
IPR = International Price Referencing
JKN = Jaminan Kesehatan Nasional
MIT = Malaysia, Indonesia and Thailand
MNC = Multinational Corporation
MOH = Ministry of Health
MOPH = Ministry of Public Health
MYR = Malaysian Ringgit
NADFC = National Agency of Drug and Food Control
NCD = Non-communicable Disease
NLED = National List of Essential Drugs
NPRA = National Pharmaceutical Regulatory Agency
OTC = Over-the-counter
PICS = Pharmaceutical Inspection Co-operation Scheme
R&D = Research & Development
RCEP = Regional Comprehensive Economic Partnership
SEA = Southeast-Asia
SME = Small and Medium-sized Enterprises
SSS = Social Security Scheme
THB = Thai Baht
TTP = Transpacific Partnership
UCS = Universal Coverage Scheme
US = United States
USD = United States Dollar
VAT = Value Added Tax
WHO = World Health Organization

Appendix 3: Pharmaceutical Industry Supply Chain



Source: Own illustration based on (PwC 2020)

Appendix 4: Revenues of Top 10 National Pharmaceutical Markets Worldwide in 2020



Source: Own illustration based on (Mikulic 2021)

Appendix 5: Description and Reasoning of Country Selection Variables

Dimension	Variable	Description and Reasoning	Weight
Market Size	<u>Population Ages 65 and Above (% of Total Population)</u>	“Population ages 65 and above as a percentage of the total population. Population is based on the de facto definition of population, which counts all residents regardless of legal status or citizenship.”	2%
	<u>Urban Population (% of Total Population)</u>	“Explosive growth of cities globally signifies the demographic transition from rural to urban and is associated with shifts from an agriculture-based economy to mass industry, technology, and service. In principle, cities offer a more favorable setting for the resolution of social and environmental problems than rural areas. Cities generate jobs and income, and deliver education, health care and other services”	2%
	<u>Population Density</u>	“Population density is midyear population divided by land area in square kilometers. Population is based on the de facto definition of population, which counts all residents regardless of legal status or citizenship--except for refugees not permanently settled in the country of asylum, who are generally considered part of the population of their country of origin. Land area is a country's total area, excluding area under inland water bodies, national claims to continental shelf, and exclusive economic zones. In most cases the definition of inland water bodies includes major rivers and lakes.”	1%
Market Intensity	<u>GDP per Capita</u>	“GDP per capita is gross domestic product divided by midyear population.”	2%
	<u>Adjusted Net National Income per Capita</u>	“Adjusted net national income is GNI minus consumption of fixed capital and natural resources depletion.”	1%
Market Growth Rate	<u>Annual Population Growth</u>	“Annual population growth rate for year t is the exponential rate of growth of midyear population from year t-1 to t, expressed as a percentage.”	9%
	<u>Annual Urban Population Growth</u>	“Urban population refers to people living in urban areas as defined by national statistical offices. It is calculated using World Bank population estimates and urban ratios from the United Nations World Urbanization Prospects.”	9%
	<u>Annual GDP per Capita Growth</u>	“Annual percentage growth rate of GDP per capita based on constant local currency. GDP per capita is gross domestic product divided by midyear population.”	9%
Market Receptivity	<u>Consumer Price Index</u>	“Consumer price index reflects changes in the cost to the average consumer of acquiring a basket of goods and services that may be fixed or changed at specified intervals, such as yearly. The Laspeyres formula is generally used. Data are period averages.”	1%
	<u>Trade (% of GDP)</u>	“Trade is the sum of exports and imports of goods and services measured as a share of gross domestic product.”	4%
	<u>Net Trade in Goods (BoP, current US\$)</u>	“Net trade in goods is the difference between exports and imports of goods. Trade in services is not included. Data are in current U.S. dollars.”	2%
	<u>Logistics Performance Index (1=low to 5=high)</u>	“Logistics Performance Index overall score reflects perceptions of a country's logistics based on efficiency of customs clearance process, quality of trade- and transport-related infrastructure, ease of arranging competitively priced shipments, quality of logistics services, ability to track and trace consignments, and frequency with which shipments reach the consignee within the scheduled time. The index ranges from 1 to 5, with a higher score representing better performance.”	2%
	<u>Foreign Direct Investment, Net Inflows (BoP, current US\$)</u>	“Foreign direct investment refers to direct investment equity flows in the reporting economy. It is the sum of equity capital, reinvestment of earnings, and other capital. Direct investment is a category of cross-border investment associated with a resident in one economy having control or a significant degree of influence on the management of an enterprise that is resident in another economy. Ownership of 10 percent or more of the ordinary shares of voting stock is the criterion for determining	5%

		the existence of a direct investment relationship. Data are in current U.S. dollars.”	
Standard of Living	<u>Life Expectancy</u>	“Life expectancy at birth indicates the number of years a newborn infant would live if prevailing patterns of mortality at the time of its birth were to stay the same throughout its life.”	1%
	<u>Unemployment Rate (% of Workforce)</u>	“Unemployment refers to the share of the labor force that is without work but available for and seeking employment. Paradoxically, low unemployment rates can disguise substantial poverty in a country, while high unemployment rates can occur in countries with a high level of economic development and low rates of poverty. In countries without unemployment or welfare benefits people eke out a living in vulnerable employment.”	3%
Digital Affinity	<u>Individuals Using the Internet (% of population)</u>	“Internet users are individuals who have used the Internet (from any location) in the last 3 months. The Internet can be used via a computer, mobile phone, personal digital assistant, games machine, digital TV etc.”	2%
Ease of Doing Business	<u>Ease of Doing Business Score (0 = Lowest Performance to 100 = Best Performance)</u>	“The ease of doing business scores benchmark economies with respect to regulatory best practice, showing the proximity to the best regulatory performance on each Doing Business indicator. An economy’s score is indicated on a scale from 0 to 100, where 0 represents the worst regulatory performance and 100 the best regulatory performance.”	12%
Country Risk	<u>Business Environment Risk</u>	“The assessment of the risk caused by default of the debtor consists primarily of a case-by-case assessment of the risk on the debtor/obligor and the trade sector and country in which it is active. Some macrofactors such as a sharp currency depreciation, high real interest rates, an economic recession or a context of widespread corruption, however, have an influence on the business environment, thereby affecting the payment capacity of all debtors/obligors in a country. The data found were presented from A-F, however they were modified to a scale of 1-7 where A=1, B=2, C=3 etc., so the smaller the number the lower the business environment risk.”	2%
	<u>Political Risk Rating</u>	“Political and assimilated events encompass all events assuming a case of force majeure for the insured or the debtor/obligor being foreign exchange shortage, political unrest such as war, revolution or riot, natural disaster and arbitrary government action. Countries are classified into seven categories (from 1 to 7) reflecting the intensity of risks arising as a result of political and assimilated events. Category 1 includes those countries for which the risk is considered the lowest and category 7 contains those countries with the highest likelihood of risks being caused by political and assimilated events.”	2%
	<u>Country Risk</u>	“The rating reflects country risk which encompasses transfer and convertibility risk and cases of force majeure (e.g. war, expropriation, revolution, civil disturbance, floods, earthquakes). The scale from 1 to 8 indicates that a higher number translates to a higher country risk.”	2%
	<u>Competitiveness Rank</u>	“The rating is made up of 98 variables organized into twelve pillars with the most important including: institutions; infrastructure; ICT adoption; macroeconomic stability; health; skills; product market; labour market; financial system; market size; business dynamism; and innovation capability. A higher score means a higher degree of competitiveness in the country.”	2%
Economic Freedom	<u>Economic Freedom Index</u>	“Economic freedom is the fundamental right of every human to control his or her own labor and property. The higher the number, the greater the economic freedom.”	2%
	<u>Political Freedom Index</u>	“Political freedom index indicates a country’s level of freedom in terms of the political situation. The higher the rank, the greater the political freedom.”	2%
Cultural Distance	<u>Cultural Distance to Germany</u>	“The measurement of cultural distance for each country in comparison to Germany as the home country is achieved by using Hofstede’s method that includes 6 dimensions: Power Distance, Individualism, Masculinity, Uncertainty Avoidance, Long Term Orientation and Indulgence.”	2%

Healthcare Specifics	<u>Domestic General Government Health Expenditure (% of GDP)</u>	“Strengthening health financing is one objective of Sustainable Development Goal 3 (SDG target 3.c). The levels and trends of health expenditure data identify key issues such as weaknesses and strengths and areas that need investment, for instance additional health facilities, better health information systems, or better trained human resources. Health financing is also critical for reaching universal health coverage (UHC) defined as all people obtaining the quality health services they need without suffering financial hardship (SDG 3.8). The data on out-of-pocket spending is a key indicator with regard to financial protection and hence of progress towards UHC.”	6%
	<u>Current Health Expenditure per Capita</u>	“Current expenditures on health per capita in current US dollars. Estimates of current health expenditures include healthcare goods and services consumed during each year.”	8%
	<u>Current Health Expenditure (% of GDP)</u>	“Level of current health expenditure expressed as a percentage of GDP. Estimates of current health expenditures include healthcare goods and services consumed during each year. This indicator does not include capital health expenditures such as buildings, machinery, IT and stocks of vaccines for emergency or outbreaks.”	7%
	<u>Burden of Disease</u>	“Disability-Adjusted Life Years (DALYs) per 100,000 individuals from all causes. DALYs measure the total burden of disease – both from years of life lost due to premature death and years lived with a disability. One DALY equals one lost year of healthy life.”	2%

Source: Own illustration based on the sources that can be found in the “Country Selection” Excel file and are accessible via hyperlink per variable

Appendix 6: Data Standardization Formula

$$x'_{ij} = \left[\frac{x_{ij} - \min_i}{R_i} * (99) \right] + 1$$

where:

x'_{ij} is the scaled final value of country j on dimension for i;

x_{ij} is the average score of country j on dimension i;

$\min_i$ is the minimum value for dimension i;

R_i is the range of dimension i.

Source: based on “Advanced Strategy” course content, Fall Semester 2021/2022 at Nova SBE

Appendix 7: Inverted Data Standardization Formula


$$1 - (x'_{ij})$$

where:

x'_{ij} is the Data Standardization Formula

Source: based on “Advanced Strategy” course content, Fall Semester 2021/2022 at Nova SBE

Appendix 8: Country Clustering Dendogram



Source: Retrieved from SPSS, can be found in the "Output Country Clustering" file

Appendix 9: Quantitative Research Questionnaire

1. In which country do you live?

Malaysia

Thailand

Indonesia

Other

2. Do you live in an urban or rural area?

Urban area (>50.000 inhabitants)

Rural area (<50.000 inhabitants)

3. How often do you buy prescription drugs?

At least once a week

At least once a month

At least twice a year

At least once a year

Other:

Generic drugs are chemical replicas of the original brand and contain the same active ingredients. Generic medicine are less expensive than brand-name ones.

4. Does your doctor (or pharmacist) more often advise you to buy generic medicine than branded medicine?

Yes

No

I don't know

5. To what extent do you agree or disagree with the following statement?

"I trust the motives and goals of pharmaceutical companies."

Strongly agree

Somewhat agree

Neither agree nor disagree

Somewhat disagree

Strongly disagree

6. Which aspects impact your perception of trust towards the pharmaceutical industry? Tick all that apply.

Prices

Intentions of the industry

Doctor's opinion

Own experience or experience of family and friends

Degree of transparency on clinical research data

Potential cooperation with government

Public reputation

Other:

7. In your opinion, how trustworthy are small pharmaceutical companies on a scale from 1 (not trustworthy) to 5 (very trustworthy)? Here, small pharmaceutical companies are companies with less than 250 employees.



8. In your opinion, how trustworthy are big pharmaceutical companies on a scale from 1 (not trustworthy) to 5 (very trustworthy)? Here, big pharmaceutical companies are companies with more than 250 employees.



9. In your opinion, how trustworthy are local pharmaceutical companies on a scale from 1 (not trustworthy) to 5 (very trustworthy)?



10. In your opinion, how trustworthy are international pharmaceutical companies on a scale from 1 (not trustworthy) to 5 (very trustworthy)?



11. In your opinion, how trustworthy are European pharmaceutical companies on a scale from 1 (not trustworthy) to 5 (very trustworthy)?



12. Which European countries do you trust the most regarding pharmaceutical expertise?
(Selection of two maximum)

France

Germany

Italy

Spain

UK

I don't know

13. Since COVID 19, did your perception of trust regarding the pharmaceutical industry change?

Yes, more trust-worthy image

Yes, less trust-worthy image

No, same perception

Other:

14. When deciding on a pharmaceutical brand/product, which factors influence your choice?
Tick all that apply.

Price

Reputation of brand

Doctor's recommendation

Country of origin of brand

Country of manufacture of product

Efficacy of consumer research data

Transparency on clinical research data

Transparency of production process

Other:

15. What could increase your trust in pharmaceutical companies? Tick all that apply.

More publicly available information about safety and efficacy

Lowered drug prices

Transparency on clinical research data

Transparency of production process

Marketing activities

Other:

16. How old are you?

<15 years

15-29 years

30-44 years

45-54 years

55-64 years

>65 years

Prefer not to say

17. What gender do you identify with?

Male

Female

Non-binary / diverse

Prefer not to say

Appendix 10: Profiles of Experts

[Click here](#) to access the link to all expert interview transcripts.

Expert	Profile
Expert 1 (E1) Maximilian Rödder	Company: Simon-Kucher & Partners Role/Position: Senior Director, Healthcare and Lifesciences Country of residence: Germany Expertise: Pharmaceutical industry in Germany, Europe, and basic knowledge of Asian markets
Expert 2 (E2) Uwe Hurth	Company: Ursapharm Arzneimittel GmbH Role/Position: Area Manager Asia & Pacific Country of residence: Germany Expertise: - Pharmaceutical industry in Germany and Asia Pacific region; MIT - Partnership Development and Market Entry
Expert 3 (E3) Ying Chen	Company: Bayer Role/Position: Head of Commercial Operations Asia Pacific Country of residence: Singapore Expertise: - Pharmaceutical industry in Asia Pacific; MIT - Marketing & Sales, Commercialization and Market Access
Expert 4 (E4) Anna Hein	Company: Midas Pharma GmbH Role/Position: Launch Manager Country of residence: Germany Expertise: - Pharmaceutical industry in Germany, Europe, and basic knowledge of Asian markets - Pharmaceutical background and Supply Chain and Launch Management
Expert 5 (E5) Jan Weiser	Company: Simon-Kucher & Partners Role/Position: Managing Partner, Healthcare and Life Sciences Country of residence: Singapore Expertise: - Healthcare and Life Sciences in SEA, China, and Australia/New Zealand; MIT - Consulting national and international clients in strategy, pricing, and sales
Expert 6 (E6) Joshua Siow	Company: Simon-Kucher & Partners Role/Position: Director, Healthcare and Life sciences Country of residence: Singapore Expertise: Healthcare and Life Sciences in APAC; MIT
Expert 7 (E7) Jamaludin Elis	Company: Chulia Pharma Sdn Bhd Role/Position: CEO Country of residence: Malaysia Expertise: - Pharmaceutical industry in Malaysia and basic knowledge of Thailand's and Indonesia's market - Overall commercial activities involving Marketing Strategies, Market Penetration and Market Expansion
Expert 8 (E8) Renaat Janssen	Company: Alvogen Role/Position: Executive Vice president APAC Country of residence: Thailand Expertise: Pharmaceutical industry in APAC; MIT

	Market Entry Strategy, Business Process Improvement and Implementation In-dept Knowledge Asia
Expert 9 (E9) Low Jin Ren Max	Company: Teraju Pharma Malaysia Role/Position: Group CEO Country of residence: Malaysia Expertise: - Pharmaceutical industry in Malaysia - Corporate Strategy, International and Domestic Business Development
Expert 10 (E10) Simone Lee	Company: Tigas Alliance Role/Position: Founder and CEO Country of residence: Malaysia Expertise: - Pharmaceutical industry in Malaysia - Pharmacy Healthcare industry, Go to Market Channel Strategy and Marketing Advisory
Expert 11 (E11) Liew Shaw Kang	Company: Zuellig Pharma Role/Position: Senior Brand Manager - Consumer Healthcare Country of residence: Malaysia Expertise: - Pharmaceutical industry in Malaysia - Consumer Healthcare, Market Conditions and Customer Buying Habits
Expert 12 (E12) Anonymous Interviewee	Company: Self employed Role/Position: Independent Consultant, Pharma and Healthcare Country of residence: Indonesia Expertise: - Pharmaceutical industry in Indonesia and basic knowledge of Thailand's and Malaysia's market - Market Access, Business Development and Regulatory Requirements
Expert 13 (E13) Anonymous Interviewee	Company: AstraZeneca Indonesia Role/Position: Director, Market Access, Government Affair and Regulatory Affair Country of residence: Indonesia Expertise: - Pharmaceutical industry in Indonesia - Market Access, Manufacturing, Supply Chain and Commercial and External Affair
Expert 14 (E14) Anonymous Interviewee	Company: Role/Position: Supply Chain Consultant Country of residence: Hongkong SAR Expertise: - Pharmaceutical industry in Thailand and Indonesia and basic knowledge of Malaysia's market - Supply Chain Optimization & Transformation
Expert 15 (E15) Benjamin Hadsik	Company: Zuellig Pharma Role/Position: Vice President and Head of Strategic Partnerships & Business Development Country of residence: Thailand Expertise: - Pharmaceutical industry in Thailand - Strategic Marketing and Business Development

Appendix 11: Discussion Guides for Expert Interviews

Discussion Guide 1: German Pharmaceutical Companies Active in Asia

1. Interviewee Introduction

1. Could you please briefly introduce yourself, your role in the company etc.?

2. Healthcare Sector and specifically Pharma Industry

2. What are the biggest opportunities in the healthcare and pharma industry, especially for German companies?
3. What are the biggest risks in the healthcare and pharma industry, especially for German companies?
4. How will the pharma industry develop in the next 10-20 years?
5. How would you describe the expertise of the German pharma industry? What makes it so special?

3. Business Activities in Asia

6. Did you expand to an Asian country/countries? If yes, which one(s) specifically? When did you decide to expand? // What type of strategy/mode of entry are used when entering the Asian markets? And why?

3.1 Country Choice & Reasoning

7. What were your motives to expand to Asia? Why did you choose this specific country/these countries?
8. How would you describe the current development, growth potential and challenges in this country?

3.2 Entry Mode

9. Which type of strategy/mode of entry did you use when entering the “foreign market”? And why?

3.3 Market Entry Process

10. What are in your opinion the main advantages/opportunities of expanding your business to Asia/MIT?
11. What challenges did your company expect before the internationalization? What are/were actual challenges that your company experienced?
12. What are main barriers when entering Asian countries/MIT?

3.4 Legal/Regulative Processes

13. What are some of the legal requirements and regulations that you faced when expanding to Asia/MIT?

3.5 Competitive Landscape

14. How would you describe the current competitive landscape in MIT? How dense is the pharmaceutical competition? What are the main competitors?
15. Do you have insights about foreign competitors? (Company names, intensity/density)

3.6 Distribution (Local Contacts)

16. Could you give us an overview about your supply chain process in Germany? And how it is in Asia/MIT?
17. Can you tell me about your relationship with local business partners in Asia/MIT and how you approached them?
18. Can you tell me about your relationship with further local contacts in Asia/MIT and how you approached them? E.g. public authorities, government, administration etc.

3.7 Cultural Differences

19. Did you face issues regarding cultural differences? If yes, what was the impact and how did you approach the cultural differences?

3.8 Perceived Opportunities & Risks

20. What are the main opportunities for German pharmaceutical SMEs in Asia? (specifically Malaysia/Indonesia/Thailand)
21. What are the main risks for German pharmaceutical SMEs in Asia? (specifically Malaysia/Indonesia/Thailand)
22. What are main barriers for German SMEs to enter Asian countries? (specifically Malaysia/Indonesia/Thailand)
23. What advice would you give to German pharmaceutical SMEs trying to expand to Asia? (specifically Malaysia/Indonesia/Thailand)
How would you approach an expansion project to Asia as a German pharmaceutical SME?

Discussion Guide 2: Local Companies With Origin in MIT

1. Interviewee Introduction

1. Could you please briefly introduce yourself, your role in the company etc.?

3. Healthcare Sector and specifically Pharma Industry

2. What are the biggest opportunities in the healthcare and pharma industry?
3. What are the biggest risks in the healthcare and pharma industry?

4. Business Activities in MIT

4. How would you describe the development of the pharma industry in the last 10 years? And how is the current situation in MIT?
5. What are the main strengths of the MIT pharmaceutical industry?
6. What are the main challenges of the MIT pharmaceutical industry?

4.1) Competitive Landscape

7. How would you describe the current competitive landscape in MIT? How dense is the pharmaceutical competition? What are the main competitors?
8. Do you have insights about foreign competitors? (Company names, intensity/density)

4.2) Supply Chain

9. Could you give us an overview about your supply chain process in MIT?

4.3) Distribution (Local Contacts)

10. Can you tell me about your relationship with local business partners in MIT. What advice would you give foreign companies when approaching local business partners?
11. Can you tell me about your relationship with further local contacts in MIT and how you approached them? E.g. public authorities, government, administration etc. What advice would you give foreign companies when approaching local contacts?

4.4) Starting a Business in MIT

12. Do you have any insights about starting a pharmaceutical business in MIT? What advice can you give foreign pharma companies when entering the MIT market?
13. What are some of the legal requirements and regulations that you faced when starting your business in MIT?

4.5) Perceived Opportunities & Risks


14. What are the main opportunities for foreign pharmaceutical SMEs in MIT?
15. What are the main risks for foreign pharmaceutical SMEs in MIT?
16. What are main barriers for foreign SMEs to enter MIT?
17. What advice would you give to foreign pharmaceutical SMEs trying to expand to MIT?

Appendix 12: Healthcare Expenditure Malaysia 2019 – 2021

	2019	2020	2021
Total health expenditure (in millions USD)	13,047.19	13,344.55	15,206.15
Total health expenditure as % of GDP	3.8	4.2	4.5
Public health expenditure – Total (in millions USD)	6,828.86	6,967.94	7,964.56
Private health expenditure – Total (in millions USD)	6,218.34	6,376.61	7,241.59
Private health expenditure – Out of pocket (in millions USD)	4,510.95	4,599.46	5,266.20

Source: Own illustration based on (GlobalData 2022b)

Appendix 13: Porter's Five Forces for Malaysia



Source: Own illustration based on literature review and findings of expert interviews

Appendix 14: Healthcare Expenditure Thailand 2019 – 2021

	2019	2020	2021
Total health expenditure (in millions USD)	17,984.02	18,163.88	18,706.98
Total health expenditure as % of GDP	3.8	4.1	4.1
Public health expenditure – Total (in millions USD)	13,434.71	13,563.71	13,984.19
Private health expenditure – Total (in millions USD)	4,549.31	4,600.18	4,722.82
Private health expenditure – Out of pocket (in millions USD)	1,559.15	1,576.46	1,625.47

Source: Own illustration based on (GlobalData 2022c, 26)

Appendix 15: Thailand 4.0

1 – 5 years	5 – 10 years	10 – 15 years
• Effective production of generic drugs • Deploy disability robot • Promote “Health Tourism”	• Use standardised medical robot • Use automated diagnostic devices • Develop new biomaterial for cancer and allergies	• Use automation to aid surgery • Develop targeted therapy • Implement implanted-device

2017

2032

Source: Own illustration based on (PwC 2017b)

Appendix 16: Porter’s Five Forces for Thailand




Source: Own illustration based on literature review and findings of expert interviews

Appendix 17: Healthcare Expenditure Indonesia 2019 – 2021

	2019	2020	2021
Total health expenditure (in millions USD)	29,316.86	30,958.61	32,900.77
Total health expenditure as % of GDP	2.9	3.1	3.1
Public health expenditure – Total (in millions USD)	14,377.36	15,196.87	16,134.52
Private health expenditure – Total (in millions USD)	14,939.50	15,761.73	16,766.25
Private health expenditure – Out of pocket (in millions USD)	10,037.33	10,576.33	11,235.239

Source: Own illustration based on (GlobalData 2022a, 18; World Bank 2021b)

Appendix 18: Top 10 Pharma Companies in Indonesia



Source: Own illustration based on (Pharma Boardroom 2021)

Appendix 19: Porter's Five Forces for Indonesia


Threat of New Entry		
▪ The industry is difficult, new entrants face challenges with the economics of scale, access to distribution channels, and government policy ▪ High for generics ▪ Low for innovative products ▪ In recent years, government started to actively attract foreign investors		
Bargaining Power of Suppliers	Competitive Rivalry	Bargaining Power of Buyers
▪ High due to the limited number of raw material suppliers in Indonesia ▪ Over 90% of raw materials must be imported primarily from China and India	▪ Highly competitive and fragmented pharmaceutical market ▪ Majority of companies are local players ▪ Government is prioritizing local generics over patented drugs	▪ Government favors local generic firms for the JKN ▪ Moderate for innovative products ▪ High for generics due to low switching costs ▪ Low for end-consumers regarding prescription medicines
Threat of Substitution		
▪ High for generics due to the high local generics competition ▪ Lower for innovative products ▪ Compulsory licensing allows government to produce drugs under patents ▪ Demand for generics compared to branded drugs increased due to cost containment pressures		

Source: Own illustration based on literature review and findings of expert interviews

Appendix 20: Further Overarching Findings of Expert Interviews

Expert	Overarching Findings
E1	E1 goes into more detail about what sets German SMEs apart. The first factor E1 mentions is that many German SMEs are family-owned, citing Boehringer Ingelheim and Merck as examples. The main advantage of family-owned businesses is their long investment horizon and their ability to make long-term strategic decisions, as they are not required to produce quarterly reports. According to E1 this can be a competitive advantage of German pharmaceutical SMEs since development cycles in the pharma industry are very long. Another factor highlighted by E1, which is also consistent with the literature analyzed, is the scientific expertise of Germany, which has a strong scientific community that provides great competition to the US. Also worth mentioning here is the vaccine expertise, which due to the pandemic has been strengthened in Germany by for example BioNTech. Moreover, it is critical for German firms to develop a solid hypothesis regarding possible political and economic developments in the long run. More specifically, E1 recommends learning the lessons from past developments within the pharmaceutical industry in MIT to be prepared for future eventualities. E1 explains that the understanding of both the revenue side and the cost side of business can be tough in MIT. The revenue side involves due diligence. The cost side means making estimations of needed investment, upcoming costs and expected price levels and sales volume.
E2 & E5	Moreover, E2 and E5 indicate the waiting time for responses of the local authorities can take a long time and is oftentimes vaguely stated. Furthermore, an evaluation of the respective culture and potential cultural differences is essential in choosing the right market.
E3	Furthermore, E3 stresses that showing clear commitment to the MIT region, having “the right level of ambition” and adapting an “investment mindset” is crucial to be able to cope with the market access and commercialization related challenges. E3 states that the entry mode and success in SEA markets does less depend on the size of the company but more on the type of product portfolio and competitive advantage. However, despite whether competing on a lean production cost model or unique research capabilities it is highlighted that, when focusing on a generic portfolio, scaling plays a more important role compared to a focus on an innovative portfolio. In this case, companies might only need one or two products, if they are “blockbusters”.
E8	According to E8, „in all of the markets, there was a threat to go to self medication. Everyone became Dr. Google, you saw amazing trends, in food supplements, and vitamins, those kinds of things. And you saw a drop of people becoming compliant in taking their doses that they need to take on a daily base. So they saw reduction, you saw a reduction in people going to the hospitals.“

Appendix 21: Hofstede Cultural dimensions - Comparison of Germany with MIT



Source: Own illustration based on (Hofstede Insights 2022)